Next Article in Journal
Preparation of Silica Aerogels by Ambient Pressure Drying without Causing Equipment Corrosion
Previous Article in Journal
Characterization of New Polyphenolic Glycosidic Constituents and Evaluation of Cytotoxicity on a Macrophage Cell Line and Allelopathic Activities of Oryza sativa
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 23
Issue 8
10.3390/molecules23081934
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Cytoprotective Characterization of 8-Hydroxyquinoline Betti Products

by
Iván Kanizsai
1,*,
Ramóna Madácsi
1,
László Hackler Jr.
1,
Márió Gyuris
1,
Gábor J. Szebeni
1,
Orsolya Huzián
2 and
László G. Puskás
1,2,*
1
Avidin Ltd., Alsó kikötő sor. 11D, H-6726 Szeged, Hungary
2
Avicor Ltd., Alsó kikötő sor. 11D, H-6726 Szeged, Hungary
*
Authors to whom correspondence should be addressed.
Molecules 2018, 23(8), 1934; https://doi.org/10.3390/molecules23081934
Submission received: 11 July 2018 / Revised: 31 July 2018 / Accepted: 31 July 2018 / Published: 2 August 2018
(This article belongs to the Section Medicinal Chemistry)
Browse Figures
Versions Notes

Abstract

:
The 8-hydroxyquinoline pharmacophore scaffold has been shown to possess a range of activities as metal chelation, enzyme inhibition, cytotoxicity, and cytoprotection. Based on our previous findings we set out to optimize the scaffold for cytoprotective activity for its potential application in central nervous system related diseases. A 48-membered Betti-library was constructed by the utilization of formic acid mediated industrial-compatible coupling with sets of aromatic primary amines such as anilines, oxazoles, pyridines, and pyrimidines, with (hetero)aromatic aldehydes and 8-hydroxiquinoline derivatives. After column chromatography and re-crystallization, the corresponding analogues were obtained in yields of 13–90%. The synthesized analogs were optimized with the utilization of a cytoprotection assay with chemically induced oxidative stress, and the most active compounds were further tested in orthogonal assays, a real time cell viability method, a fluorescence-activated cell sorting (FACS)-based assay measuring mitochondrial membrane potential changes, and gene expression analysis. The best candidates showed potent, nanomolar activity in all test systems and support the need for future studies in animal models of central nervous system (CNS) disorders.

Graphical Abstract

1. Introduction

In the last two decades, the 8-hydroxyquinoline (8-HQ) structure have emerged as a promising pharmacophore scaffold for medicinal chemists, due to a coded biological and synthetic potential owing to the active sites in the molecule on C-2, C-5, and C-7 carbons [1]. The presence of hydroxyl substituent on the C-8 carbon creates an ortho (C-7) and/or para (C-5) direction, providing active positions for electrophilic aromatic substitutions on C-5 (para) and for the accomplishment of aza Fiedel-Crafts-type reactions, including Mannich- or Betti-three components reactions (Mannich-3CR and Betti-3CR) predominantly on the C-7 (ortho) position. Higher molecular diversity and the formation of a new chiral carbon centre could be achieved by the use of Betti-3CR: treatment of several (aromatic) aldehydes with primary amines then 8-HQ, 5-nitro-, or 5-chloro-8-HQ. The application of Mannich-3CR of simple formaldehyde and secondary amines as an iminium source for addition, is highlighted for biological utilization [2,3]. Based on previously published biological studies, the structurally modified 8-HQs exert two main activities depending on the C-7 function and substitution pattern of the mother compound, 8-HQ. These compounds are either cytotoxic or active in cytoprotection assays. These studies describe a variety of 7-aminomethylated 8-HQ, 5-chloro-8-HQ and 5-nitro-8-HQ (nitroxoline) as products of different multicomponent reaction (MCR) techniques in different hit-to-lead optimizations.

1.1. Cytotoxicity

The most promising cytotoxic 8-HQ analogues were depicted in Figure 1. They act through different mechanisms, namely the inhibition of Cathepsin B, KDM4 histone demethylases, 2-oxyglutarate oxygenase subtypes, and lipoxygenase (LOX)-enzymes [4,5,6,7,8,9,10]. Among the enzyme inhibitors, eutomer (−)-Betti products were presented with excellent, selective 12-LOX inhibition; moreover, these products were tested successfully in in vivo experiments. Additionally, INP1750 has a Gram-negative pathogen selective antibacterial effect [11]. Interestingly, if an N-sulfonated piperazine-1-yl unit was introduced in the C-7 position, the Mannich derivatives exerted an improved growth-inhibitory effect that was 26-fold more potent than that of 5-chloro-8-HQ against HeLa cells [12,13].
It is notable that the inhibitor activities were explained by an improved metal chelating ability compared with the parent compound 8-HQ, due to optimal copper and zinc(II)-binding in vivo [1,6,11,12,14].

1.2. Cytoprotection

In contrast with mentioned enzyme inhibition and antitumor activities, a number of 8-HQ derivatives possessed cytoprotective activities.
As a suitable example, clioquinol (CQ, 5-Chloro-7-iodoquinolin-8-ol) has a selective, but low binding ability for Zn2+/Cu2+-ions, and it exerts potency against several neurodegenerative disorders (Huntington, Alzheimer’s, and Parkinson diseases) but its toxicity in long-term administration restricts its use in the clinic [15,16,17,18]. Structural modifications on the parent compound CQ have afforded second generation Zn2+/Cu2+ ionophores such as the PBT family (C-2 substituted 5,7-dichloro-8-HQ e.g. PBT2 (5,7-Dichloro-2-[(dimethylamino)methyl]quinolin-8-ol)) or their related structures, which have increased blood brain barrier permeability, more solubility, and less toxicity. In addition, PBT2 progressed to Phase IIa clinical trials as an anti-Alzheimer agent [19,20,21,22]. The multifunctional characteristics of these 8-HQ analogs provide the basis for the emerging use of multitarget-directed ligand (MTDL) treatment of neurogenerative diseases possessing a multifactorial nature e.g., Alzheimer’s disease.
An interesting medicinal chemistry concept is based on the formation of 8-HQ-hybrids (Figure 2). Known pharmacophores e.g. propargil or N-benzyl piperidine/piperazine moieties were substituted in C-2, C-5, or C-7 positions of 8-HQ creating analogues with an improved cytoprotective action. In fact, a series of 2- and 5-functionalized-8-hydroxyquinoline hybrid structures, HLA-20, M30, VK28, and MTDLs act as potent anti-neurodegenerative agents, exert significant inhibition of β-amyloid aggregation in vitro, decrease metal-driven oxidative damage and β-amyloid-mediated neurotoxicity. In addition, considerable cholinesterase inhibition, ROS scavenging, and an anti-aggregating effect on Aβ42 has been assessed [23,24,25,26,27,28,29,30,31,32,33,34,35,36]. These compounds incorporate known pharmacophore synthones from rasagiline (HLA20), donepezil (MTDL3 and MTDL4), or from rivastigmine (VK28). As a result of original framework combinations, a subclass of C-7-hybrides were also prepared by fusing N-benzyl piperazines/piperidines to 8-HQ, utilizing optimized Mannich-3CR conditions [37].
Interestingly, C-2 hydrazones, thiosemicarbazones, and semicarbazones modulate the Cu-Aβ peptide interactions as well. 8-HQ-2-hydrazones (INHHQ) were proved to be well-tolerated, stable derivatives which are able to cross the blood-brain barrier (BBB) and act as anti-Parkinson agents [38,39].
Phenotypic screening for functionally distinct 8-HQ derivatives on a yeast TAR DNA-binding protein 43 (TDP-43) toxicity model indicated a considerable reverse action for the expression of the TDP-43 protein in the case of compound HQ415 (Figure 2) [40]. Moreover, CQ can modulate amyloidogenic proteins/peptides and consequently it can be effective in Alzheimer’s disease, but its structural modifications towards Betti-bases (e.g., HQ415) resulted in significantly higher potency in neuronal proteotoxicity models, presumably due to having an effect on the process of oxidative stress and misregulation of iron metabolism besides enzyme inhibition [41].
Novel cytoprotective screening assays revealed Betti-bases as being a new subclass of potent cytoprotective agents; nevertheless, a few number of analogues had been analyzed up to now (Figure 2). During the utilization of a cell-microelectronic sensing technique (RT-CES), a small-membered Q-library, composed of seven commercially available 8-HQ analogues, was tested for cytoprotective activity in real-time to identify possible hit compound(s) against cardiac diseases. Notably, compound Q3 implicated 8-HQ, benzocain, and benzaldehyde motifs, emerging as a suitable candidate for a hit-to-lead optimization [42]. Systematic preparative efforts led to the analogue Q50, which was proven to be highly potent in improving cardiac functional recovery of ischemic/reperfused myocardium in rats [43].
The current work describes the optimization of the 8-HQ Betti products for cytoprotective activity in glioblastoma cells as a model for neuroprotection, as well as for possible application in CNS-related disorders.

2. Results and Discussion

Scheme 1 depicts the general synthetic procedures for the synthesis of products 1–48. For a comprehensive biological evaluation, several primary aromatic amines, aromatic aldehydes and 8-hydroxyquinolines were subjected to the Betti-3CR. Notably, the achievement of a suitable optimal condition and access to a large number of Betti-compound libraries is a great challenge, owing to the fundamental Betti-conditions that proceed with very poor yields, and its improvement is strongly dependent on the applied amine and/or aldehyde components.
For a rapid synthetic method, a known industrial application was chosen to access a diverse chemical library. For the assemblies, 1 v/v % formic acid was exploited as Brönsted-acid mediator in acetonitrile at 75 °C. We focused on the preparation of Betti compounds with high purities regardless of the yields and optimal conditions.
At first, an optionally selected 15-membered basic library was prepared and assessed in a cytoprotection assay to reveal the possible next step for a synthetic strategy. Following a medicinal chemistry protocol, the 8-HQ was conducted by means of simple amine inputs such as aniline, 2-aminopyridine, 2-aminopyrimidine, and 3-aminoisoxazol in combination with unsubstituted benzaldehyde and 2-pyridinecarbaldehyde as a N-containing substrate. In addition, several structural modifications were accomplished to prepare some substituted variants by altering either the amine or aldehyde components. In accordance with that, 10 other examples were synthesized using substituted benzaldehydes, containing electron withdrawing (CF3, F, and NO2) or electron donating (O-alkyl) group in the para position, in combination with e.g., benzocain, p-benzoic acid (PABA), 5-alkyl (methyl or tert-butyl)-substituted isoxazoles, or 6-picoline.
For pyrimidine based analogues, only two derivatives were presented, consisting of unsubstituted pyrimidine units with phenyl (from benzaldehyde) or 4-nitrophenyl (from p-nitrobenzaldehyde) moieties.
In all cases, the formic acid-mediated Betti-transformations were accomplished to furnish the pure desired products 1–15 in yields of 12–40% (Scheme 2).

2.1. Primary Assay

We have utilized a simple and inexpensive method to screen our 8-HQ analogs for cytoprotective activity. U251 MG glioblastoma cells were exposed to hydrogen peroxide to induce oxidative stress, and the effects of co-treatment with the synthesized compounds were investigated after a 24 h incubation by a fluorimetric endpoint assay. Cytoprotective compounds could be identified by resulting in more live cells after a peroxide challenge.

2.2. Structure Activity Relationship

Gratifyingly, the first assessment delineated a preliminary structure-activity relation (SAR), and demonstrated a high cytoprotective potential, due to the Betti-structure. In fact, we observed sub-micromolar activities in most cases, except for compounds 5 and 7 (1.05 µM and 2.03 µM). Consequently, application of PABA and non-substituted isoxazoles as an amine source is not suggested for further application. Despite that, presence of an alkyl function on C-5 position for the isoxazole ring significantly increases the efficiencies, as shown in case of compounds 8–10 (IC50 (8–10) = 0.15, 0.49, and 0.25 µM). Interestingly, substitutions of the amine or aldehyde are capable of enhancing the cytoprotective activity as demonstrated by the changing IC50 values in the range from 2.03 µM towards 0.11 µM. Based on these preliminary results, we assumed that it was possible to increase the scaffold’s potential; however, the perfect substitution pattern could not be drawn due to similar sub-micromolar activities for differently oriented substitution patterns in starting substrates.
Accordingly, further synthetic efforts could not be limited to one mainstream biological optimization process, with a focus on the variation of either the amine or the aldehyde reagents; rather, our strategy is based on the construction of a chemical library involving three subclasses (substituted anilines (Subclass 1), 2-aminopicolines (Subclass 2) and 2-aminopyrimidines (Subclass 3)) to demonstrate structure-activity relations and to give a chance to select lead-like compounds for the final assessment.
Coupling of benzocaine (presence of para-COOEt group) instead of aniline with 4-CF3–benzaldehyde and 8-HQ slightly attenuated the biological activity of derivative 16 from 0.15 µM (for 2) to 0.19 µM (Table 1). On the other hand, slightly better results were obtained by the substitution of R″ = 4-F–C6H4 (analogues 4; IC50 = 0.11 µM) with a 2-pyridyl group (analogues 17; IC50 = 0.12 µM). Interestingly, the application of benzocaine for the construction of a 2-pyridyl-containing analogue 17 improved the cytoprotection potential significantly (compound 3 with IC50 = 0.40 µM in comparison with 17, IC50 = 0.12 µM). Moreover, replacement of the carbetoxy group with a NO2 or CF3 moiety resulted in synthesized compounds with excellent efficiency in cytoprotection, with 0.09 µM (R′ = 4-CF3–C6H4 and R″ = 2-pyridyl; compound 18) and 0.12 µM (R′ = 4-NO2–C6H4 and R″ = 2-pyridyl; compound 19) IC50 values.
From Subclass 1, three superior compounds 17 and 18 besides analogue 4 were selected as lead-like compounds.
For the picoline family, basic compounds 6, 11, 12, and 13 highlighted the suitable reagent combination, such as para-substituted aldehydes, regardless of the electronic nature of the substituents and/or 6-picoline. Moreover, incorporation of the R″ = 2-pyridyl unit in compound 13 (IC50 = 0.687 µM) resulted in a weak cytoprotective potential in comparison with benzaldehyde-based analogues 11 (R″ = 4-F–C6H4; IC50 = 0.158 µM) and 12 (R″ = 4OCH(CH3)2–C6H4; IC50 = 0.289 µM). Although, both of electron withdrawing group (EWG)- or electron donating group (EDG)-substituted analogues possess higher activity than the unsubstituted such as compound 6 or the 2-pyridylform 13, 11 with para-fluoro moiety on the R″ position demonstrated better efficiency.
In a pyridine-based optimization a tendency could be outlined by introducing a para–trifluoromethyl or para–nitrophenyl group on the R″ function, causing a remarkable positive effect. For a first improvement, the tested analogues 20 and 21 exerted excellent activity with IC50 = 0.087 µM and 0.086 µM values. Notably, their representative C-2 methylated variant 23 had diminished cytoprotection levels, thus the 8-hydroxyquinaldine proved to be an unsuitable component for the development process. Afterwards, we considered the in-vivo or in-use feasibilities of nitro and trifluoromethylated derivatives in future studies. For possible toxicity issues therefore, we decided that the trifluoromethylated structure 20 would be the favored scaffold for further modification, and that the development of nitro derivatives was terminated. In the next steps, the positions of the trifluoromethyl and the picolines methyl group were varied, resulting in a slightly decreased IC50 range: 0.156–0.166 µM were observed for cases 25–27. Interestingly, application of di-substituted aldehydes involving trifluoromethyl and/or fluoro substituents in 2,4-; 3,4-, and 3,5-positions resulted in molecules 28–32, which displayed a decreased biological activity with an IC50 = 0.204 µM at best (Table 2). Based on these observations, 20 and 21 picoline derivatives were selected for the final study.
Although the preliminary test defined high potential derivatives 14 and 15 with the introduction of a non-substituted pyrimidine moiety (IC50 values 0.233 µM and 0.106 µM), additional transformations should be accomplished that focus on the impact of replacing of CF3 with either EWG groups or ED functions. Also, the influence on the activity of further substituents on the phenyl ring was tested. In addition, further efforts were taken to determine the importance of introducing a methyl moiety on the pyrimidine heterocycle. Exploiting the earlier presented method, 16 analogues were prepared, with yields of up to 68% (Table 3). Except for 33 (besides the compound 14 and 15), all Betti-products were derived from the 4-methyl-2-amino-1,3-pyrimidine as amine input. The firstly-prepared 33, with a 4-CF3–C6H4 function on the R″ position, demonstrated a slightly better effect in comparison with R″ = C6H5 (14) or 4-NO2–C6H4 (15). Gratifyingly, the introduction of a methyl on the pyrimidine ring also increased the cytoprotection activity. For R″ = 4-NO2–C6H4 (35), a similar IC50 value (0.114 µM) was observed. Replacing CF3 with SF5 (36) or halogenides such as fluorine (37), bromine (38), or iodine (39) slightly attenuated the efficiency. Interestingly, the combination of 4-chlorobenzaldehydes, 4-methyl-2-amino-pyrimidine, and 8-HQ afforded one of the most potent derivatives, 40, with a 73-nM IC50 value. Despite that, the 2,4- or 3,5-disubstituted phenyl moieties reduced the bioactivities; however, an acceptable cytoprotection level was provided by the incorporation of the 2,4-CF3–C6H3 group (compound 43, IC50 = 0.119 µM). Modification on the pyrimidine structure, replacing methyl into a bromine unit decreased the activity to 0.183 µM, while a solubility issue also occurred in that case. The presence of an electron-donating group on the R″ position (analogue 47, IC50 = 0.481 µM) or a C-2 methyl function (derivative 48, IC50 = 0.887 µM) diminished the cytoprotective potential.
According to our results, compounds 34, 35, 40, and 43 were proved to be the most potent pyrimidine derivatives and were selected for final assessment.

2.3. Evaluation of the Most Active Compounds in a Real-Time Cytoprotection Assay

In our primary assay, we have identified compounds that showed excellent activity. However, the derivatization of the basic scaffold with the combination of beneficial substitutions resulted in a handful of products with very similar activity and at the same time, significantly different modifications. Since the primary assay was unable to pinpoint one or two products that could be marked as leads, in an attempt to narrow down our selection of the most active compounds (compounds 4, 17, 18, 20, 21, 34, 35, 40, and 43 with IC50 between 0.08 and 0.12 µM) we have utilized an orthogonal assay to determine cytoprotective activity. Cell-based phenotypic screening, including end-point in vitro cellular screening protocols to identify cytoprotective compounds, are commonly used [44]; however, real-time cellular assays provide more information on the kinetics of drug action. Previously we have successfully adopted the RT-CES system to identify cytoprotective compounds [37]. Briefly, cells grown on golden electrodes in microplates were incubated with hydrogen peroxide alone or in the presence of our compounds. Using this system, cell viability can be monitored continuously with one-minute resolution through the measurement of impedance of the electrodes. The detected impedance is converted to an arbitrary measure (cell index) that is proportional to the number of attached cells, the strength of their attachment and cell morphology, since these properties influence electrode coverage.
Using this real-time technique we have determined the IC50 values for each selected compound 24 h after treatment. The calculated values were comparable to the ones determined in the primary assay, hence this assay was also unable to pinpoint a lead. Interestingly, the 4-CF3 and 4-methyl pyrimidine sidechain containing 34 performed the best with the lowest IC50 value, and significant effect (29% protection) at 110 nM concentration. Our least active compound, 48, bearing a methyl group in position 2 on the 8-HQ structure, also performed poorly in this assay. Results are summarized in Figure 3.

2.4. Mitochondrial Membrane Depolarization following Oxidative Stress is Reversed by Treatment with the Novel 8-HQ Analogs

Mitochondrial dysfunction is a prominent feature in neurodegenerative diseases, it can result in production and amplification of reactive oxygen species, and may be important in the pathophysiology of these diseases. Changes in the mitochondrial membrane potential (MMP) are detected in oxidative stress, and were suggested even as a biomarker for oxidative environmental stress [45].
The selected 10 most active analogues (compounds 4, 15, 17, 18, 20, 21, 34, 35, 40, and 43) were also tested as to whether they were able to reverse the mitochondrial membrane depolarization caused by the induced oxidative stress by hydrogen peroxide. The applied hydrogen peroxide treatment was higher in these experiments than in the previous assays (500 µM vs. 250 µM), in order to see a significant effect in the 2 h timeframe of this assay. All tested analogs effectively reversed the detected membrane depolarization. In this assay, the most active compounds (21, 34, and 43) were active even at the lowest applied 33 nM concentration. Figure 4 shows the effect of treatments compared to hydrogen peroxide treatment only (set by normalization as 1).

2.5. 8-HQ Analogues Induce Hypoxia Related Genes and Glucose Transporter Expression

The contribution of cerebrovascular deficiencies (such as cerebral ischemia/stroke) and the dysregulation of brain insulin signaling have been strongly implicated in neurodegenerative diseases in recent years [46]. Reduction of blood supply leading to a hypoxic condition is known to activate cellular responses through hypoxia-inducible factors (HIFs). The stabilization of HIF1A protein controlling the expression of stress adaptation related genes is a major factor in the oxidative stress response [47]. Since our original 8-HQ analog (Q50, 21) showed potent activity in ischemic/reperfused myocardium in rats, it was selected along with a highly active (34) and less active compounds (47, 48), and was investigated for its effect on oxidative stress response genes. Quantitative real-time PCR (qRT-PCR) analysis of the expression of oxidative stress-related genes HMOX-1, VEGF, and a glucose transporter GLUT1 was carried out.
Results depicted in Figure 5 showed significant gene activation following treatment at 100 and 300 nM concentrations in the case of 21 and 34, while gene-inducing capacity decreased parallel to cytoprotective activity with the less active compounds.

3. Materials and Methods

All NMR spectra were recorded in deuterated dimethyl sulfoxide (DMSO) at 298 K on a Bruker Avance 500 (Billerica, MA, USA) or Bruker Avance Neo 500 spectrometer (Billerica, MA, USA). All chemical shifts (δ) were reported in ppm relative to the residual solvent signal. HRMS spectra were recorded on a Thermo Scientific Q Exactive Plus mass spectrometer (Waltham, MA, USA) using a heated electrospray ionization (HESI-II) probe ion source. TLC was performed on aluminum sheets coated with silica gel 60 F254 (Merck, 1.05554, Budapest, Hungary). Visualization was done under UV light (254 nm). Column chromatography was carried out using silica gel (Merck, 60 Å, 0.063‒0.200 mm, Budapest, Hungary). Melting points were determined by a Stuart SMP10 device (Staffordshire, UK), and they were uncorrected. All chemicals and solvents were of commercial grade and were used without further purification.

3.1. General Procedure for the Syntheses of Compounds 1–48

To a solution of 1 mmol aldehyde, 3× volume of acetonitrile and 1 equivalent volume of amine were added to 0.6 equivalent of quinoline derivatives and 1% (v/v) formic acid. The reaction mixture was stirred at higher temperature (75 °C). The reaction was monitored by TLC (eluent: hexane isomeric mixture:acetone). If the product precipitated, it was filtered, washed with hexane, and dried. If the reaction mixture was homogeneous, it was evaporated to dryness and was purified by column chromatography (eluent: hexane:acetone from 20:1 to 4:1, v/v). The crude product was crystallized from hexane/ethyl-acetate. The molecular structures were determined by means of 1D and 2D-NMR technologies (see Supplementary Materials)
7-(Phenyl(phenylamino)methyl)quinolin-8-ol (1): white solid, yield: 26% (51 mg), melting point (m.p.): 141–143 °C, C22H18N2O; 1H-NMR (500 MHz, DMSO) δ 9.99 (s, 1H), 8.82 (s, 1H), 8.24 (d, J = 7.0 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.53–7.48 (m, 1H), 7.43–7.38 (m, 2H), 7.35 (d, J = 7.9 Hz, 1H), 7.32–7.23 (m, 2H), 7.24–7.14 (m, 1H), 7.01–6.92 (m, 2H), 6.67–6.59 (m, 2H), 6.49–6.42 (m, 2H), 6.14 (d, J = 5.3 Hz, 1H); 13C-NMR (126 MHz, CDCl3) δ 149.77 (s), 148.25 (s), 147.97 (s), 142.87 (s), 138.11 (s), 136.04 (s), 128.75 (s), 128.34 (s), 127.51 (s), 127.36 (s), 126.82 (s), 126.29 (s), 125.45 (s), 121.69 (s), 117.54 (s), 118.06 (s), 112.94 (s), 54.16 (s); HRMS (ESI) m/z calcd. for C22H18N2O [M + H]+: 327.1492, found: 327.1493.
7-((Phenylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (2): white solid, yield: 29% (69 mg), m.p.: 83–85 °C, C23H17F3N2O; 1H-NMR (500 MHz, DMSO) δ 10.14 (s, 1H), 8.84 (d, J = 2.2 Hz, 1H), 8.26 (d, J = 8.2 Hz, 1H), 7.67 (d, J = 7.9 Hz, 2H), 7.62 (d, J = 7.8 Hz, 2H), 7.56 (d, J = 8.5 Hz, 1H), 7.52 (dd, J = 7.7, 3.7 Hz, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.00 (t, J = 7.4 Hz, 2 H), 6.64 (d, J = 7.8 Hz, 2H), 6.55 (d, J = 6.9 Hz, 1H), 6.50 (t, J = 7.0 Hz, 1H), 6.23 (d, J = 6.9 Hz, 1H); 13C-NMR (126 MHz, CDCl3) δ 149.95 (s), 148.38 (s), 147.73 (s), 147.68 (s), 138.14 (s), 136.09 (s), 128.84 (s), 128.09 (s), 127.71 (s), 127.53 (q, J = 31.9 Hz), 126.16 (s), 125.29 (q, J = 3.3 Hz), 124.58 (s), 121.88 (s), 117.76 (s), 116.48 (s), 113.04 (s), 54.03 (s); HRMS (ESI) m/z calcd. for C23H17F3N2O [M + H]+: 395.1366, found: 395.1369.
7-((Phenylamino)(pyridin-2-yl)methyl)quinolin-8-ol (3): white solid, yield: 13% (26 mg), m.p.: 129–130 °C, C21H17N3O; 1H-NMR (500 MHz, DMSO) δ 10.16 (s, 1H), 8.86 (dd, J = 4.2, 1.5 Hz, 1H), 8.56 (dd, J = 4.8, 0.7 Hz, 1H), 8.25 (dd, J = 8.3, 1.5 Hz, 1H), 7.76 (td, J = 7.7, 1.8 Hz, 1H), 7.59–7.47 (m, 3H), 7.33 (d, J = 8.6 Hz, 1H), 7.27 (ddd, J = 7.4, 5.0, 0.8 Hz, 1H), 7.02 (dd, J = 8.1, 7.6 Hz, 2H), 6.70 (d, J = 7.8 Hz, 2H), 6.61 (d, J = 7.1 Hz, 1H), 6.50 (t, J = 7.3 Hz, 1H), 6.27 (d, J = 7.0 Hz, 1H); 13C-NMR (126 MHz, DMSO) δ 160.99 (s), 150.53 (s), 149.30 (s), 148.69 (s), 147.80 (s), 138.59 (s), 137.43 (s), 136.48 (s), 129.28 (s), 128.05 (s), 126.81 (s), 125.23 (s), 122.81 (s), 122.50 (s), 122.21 (s), 117.96 (s), 116.68 (s), 113.31 (s), 55.40 (s); HRMS (ESI) m/z calcd. for C21H17N3O [M + H]+: 328.1444, found: 328.1445.
Ethyl 4-((4-fluorophenyl)(8-hydroxyquinolin-7-yl)methylamino)benzoate (4): white solid, yield: 17% (42 mg), m.p.: 142–144 °C, C25H21FN2O3; 1H-NMR (500 MHz, DMSO) δ 10.17 (s, 1H), 8.87 (dd, J = 4.2, 1.5 Hz, 1H), 8.30 (dd, J = 8.3, 1.5 Hz, 1H), 7.64 (d, J = 8.9 Hz, 2H), 7.56 (dd, J = 8.3, 4.2 Hz, 1H), 7.51 (d, J = 8.6 Hz, 1H), 7.45–7.38 (m, 3H), 7.34 (d, J = 7.2 Hz, 1H), 7.20–7.14 (m, 2H), 6.69 (d, J = 8.8 Hz, 2H), 6.25 (d, J = 7.2 Hz, 1H), 4.18 (q, J = 7.0 Hz, 2H), 1.24 (t, J = 7.1 Hz, 3H).; 13C-NMR (126 MHz, CDCl3) δ 165.78 (s), 161.24 (d, J = 243.6 Hz), 151.80 (s), 150.01 (s), 148.42 (s), 138.11 (s), 136.11 (s), 130.78 (s), 129.38 (d, J = 8.1 Hz), 127.72 (s), 125.97 (s), 124.27 (s), 121.90 (s), 117.72 (s), 116.96 (s), 115.26 (s), 115.09 (s), 111.95 (s), 59.58 (s), 53.35 (s), 14.34 (s).
4-((4-Fluorophenyl)(8-hydroxyquinolin-7-yl)methylamino)benzoic acid (5): white solid, yield: 13% (30 mg), m.p.: 185–187 °C, C23H17FN2O3; 1H-NMR (500 MHz, DMSO) δ 12.01 (s, 1H), 10.22 (s, 1H), 8.85 (d, J = 2.2 Hz, 1H), 8.28 (d, J = 8.1 Hz, 1H), 7.69 (d, J = 7.9 Hz, 2H), 7.61 (d, J = 8.9 Hz, 2H), 7.59 (d, J = 8.4 Hz, 2H), 7.54 (dd, J = 8.0, 3.9 Hz, 1H), 7.48 (d, J = 8.5 Hz, 1H), 7.39 (d, J = 8.5 Hz, 1H), 7.31 (d, J = 6.9 Hz, 1H), 6.66 (d, J = 8.3 Hz, 2H), 6.31 (d, J = 6.7 Hz, 1H); 13C-NMR (126 MHz, CDCl3) δ 167.37 (s), 151.48 (s), 150.16 (s), 149.13 (d, J = 297.5 Hz), 148.49 (s), 146.83 (s), 138.14 (s), 136.14 (s), 131.02 (s), 128.20 (s), 127.85 (s), 126.06 (s), 125.41 (d, J = 2.8 Hz), 123.73 (s), 122.01 (s), 118.04 (s), 117.84 (s), 111.92 (s), 53.82 (s).
7-(Phenyl(pyridin-2-ylamino)methyl)quinolin-8-ol (6): white solid, yield: 25% (49 mg), m.p.: 172–174 °C, C21H17N3O; 1H-NMR (500 MHz, DMSO) δ 9.92 (s, 1H), 8.85 (dd, J = 4.0, 1.3 Hz, 1H), 8.29 (dd, J = 8.3, 1.1 Hz, 1H), 7.92 (d, J = 4.1 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.54 (dd, J = 8.3, 4.2 Hz, 1H), 7.42–7.34 (m, 5 H), 7.29 (t, J = 7.6 Hz, 2 H), 7.20 (t, J = 7.3 Hz, 1 H), 6.86 (d, J = 8.5 Hz, 1 H), 6.68 (d, J = 8.4 Hz, 1 H), 6.55–6.37 (m, 1H); 13C-NMR (126 MHz, DMSO) δ 158.43 (s), 150.00 (s), 148.69 (s), 147.90 (s), 144.00 (s), 138.57 (s), 137.12 (s), 136.47 (s), 128.62 (s), 127.86 (s), 127.66 (s), 127.04 (s), 126.95 (s), 126.36 (s), 122.05 (s), 117.73 (s), 112.51 (s), 109.26 (s), 52.08 (s); HRMS (ESI) m/z calcd. for C21H17N3O [M + H]+: 328.1444, found: 328.1447.
7-(Isoxazol-3-ylamino)(pyridin-2-yl)methyl)quinolin-8-ol (7): white solid, yield: 27% (52 mg), m.p.: 145–146 °C, C18H14N4O2; 1H-NMR (500 MHz, DMSO) δ 10.02 (s, 1H), 8.82 (d, J = 2.1 Hz, 1H), 8.49 (d, J = 3.4 Hz, 1H), 8.31 (bs, 1H), 8.24 (d, J = 8.1 Hz, 1H), 7.73 (t, J = 7.5 Hz, 1H), 7.54 (d, J = 8.5 Hz, 1H), 7.52–7.46 (m, 2H), 7.33 (d, J = 8.5 Hz, 1H), 7.27–7.12 (m, 2H), 6.35 (d, J = 7.9 Hz, 1H), 6.09 (bs, 1H); 13C-NMR (126 MHz, CDCl3) δ 162.79 (s), 160.56 (s), 158.17 (s), 149.88 (s), 148.84 (s), 148.23 (s), 138.14 (s), 136.83 (s), 136.00 (s), 127.57 (s), 126.24 (s), 124.61 (s), 122.27 (s), 121.81 (s), 121.73 (s), 117.23 (s), 97.02 (s), 55.73 (s); HRMS (ESI) m/z calcd. for C18H14N4O2 [M + H]+: 319.1190, found: 319.1189.
7-((5-tert-Butylisoxazol-3-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (8): white solid, yield: 18% (48 mg), m.p.: 185–187 °C, C24H22F3N3O2; 1H-NMR (500 MHz, DMSO) δ 10.08 (s, 1H), 8.84 (bs, 1H), 8.28 (d, J = 8.2 Hz, 1H), 7.66 (d, J = 7.8 Hz, 2H), 7.59–7.50 (m, 4H), 7.40 (d, J = 8.4 Hz, 1H), 7.10 (d, J = 7.8 Hz, 1H), 6.31 (d, J = 7.7 Hz, 1H), 5.66 (s, 1H), 1.18 (s, 9H); 13C-NMR (126 MHz, DMSO) δ 179.26 (s), 163.57 (s), 150.17 (s), 148.89 (s), 148.27 (s), 138.57 (s), 136.54 (s), 128.11 (s), 127.84 (q, J = 31.9 Hz), 126.38 (s), 125.69 (q, J = 3.9 Hz), 124.93 (s), 124.78 (q, J = 272.2 Hz), 122.35 (s), 118.05 (s), 91.12 (s), 54.54 (s), 32.63 (s), 28.89 (s); HRMS (ESI) m/z calcd. for C24H22F3N3O2 [M + H]+: 442.1737, found: 442.1739.
7-((4-Fluorophenyl)(5-methylisoxazol-3-ylamino)methyl)quinolin-8-ol (9): white solid, yield: 13% (27 mg), m.p.: 153–155 °C, C20H16FN3O2; 1H-NMR (500 MHz, DMSO) δ 9.98 (s, 1H), 8.86 (dd, J = 3.9, 1.1 Hz, 1H), 8.30 (d, J = 8.3 Hz, 1H), 7.59 (d, J = 8.5 Hz, 1H), 7.55 (dd, J = 8.3, 4.2 Hz, 1H), 7.41 (d, J = 8.7 Hz, 1H), 7.38 (dd, J = 8.4, 5.9 Hz, 2H), 7.13 (t, J = 8.8 Hz, 2H), 7.01 (d, J = 8.3 Hz, 1H), 6.23 (d, J = 8.3 Hz, 1H), 5.73 (s, 1H), 2.20 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 167.92 (s), 164.03 (s), 161.48 (d, J = 242.6 Hz), 149.95 (s), 148.76 (s), 139.56 (s), 138.55 (s), 136.49 (s), 129.32 (d, J = 8.1 Hz), 127.96 (s), 126.27 (s), 125.66 (s), 122.18 (s), 117.87 (s), 115.36 (d, J = 21.2 Hz), 94.33 (s), 54.21 (s), 12.45 (s); HRMS (ESI) m/z calcd. for C20H16FN3O2 [M + H]+: 350.1299, found: 350.1300.
7-((5-Methylisoxazol-3-ylamino)(4-nitrophenyl)methyl)quinolin-8-ol (10): white solid, yield: 26% (59 mg), o.p.: 138–140 °C, C20H16N4O4; 1H-NMR (500 MHz, DMSO) δ 10.16 (s, 1H), 8.84 (s, 1H), 8.28 (d, J = 8.1 Hz, 1H), 8.16 (d, J = 8.2 Hz, 2H), 7.61 (d, J = 8.1 Hz, 2H), 7.56–7.48 (m, 2H), 7.40 (d, J = 8.4 Hz, 1H), 7.15 (d, J = 7.7 Hz, 1H), 6.34 (d, J = 7.7 Hz, 1H), 5.74 (s, 1H), 2.18 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 167.76 (s), 163.53 (s), 150.90 (s), 149.77 (s), 148.49 (s), 146.35 (s), 138.15 (s), 136.10 (s), 128.01 (s), 127.77 (s), 125.93 (s), 124.02 (s), 123.56 (s), 122.00 (s), 117.73 (s), 93.91 (s), 54.18 (s), 12.01 (s); HRMS (ESI) m/z calcd. for C20H16N4O4 [M + H]+: 377.1244, found: 377.1250.
7-((4-Fluorophenyl)(6-methylpyridin-2-ylamino)methyl)quinolin-8-ol (11): white solid, yield: 12% (26 mg), m.p.: 157–159 °C, C22H18FN3O; 1H-NMR (500 MHz, DMSO) δ 9.97 (s, 1H), 8.82 (d, J = 2.5 Hz, 1H), 8.26 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 8.5 Hz, 1H), 7.50 (dd, J = 8.1, 4.0 Hz, 1H), 7.41–7.31 (m, 3H), 7.30–7.17 (m, 2H), 7.08 (t, J = 8.7 Hz, 2H), 6.80 (d, J = 8.4 Hz, 1H), 6.40 (t, J = 12.7 Hz, 1H), 6.33 (d, J = 6.9 Hz, 1H), 2.19 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 160.92 (d, J = 242.0 Hz), 157.50 (s), 155.70 (s), 149.53 (s), 148.29 (s), 139.82 (s), 138.13 (s), 137.24 (s), 136.04 (s), 128.95 (d, J = 8.0 Hz), 127.48 (s), 126.60 (s), 125.68 (s), 121.68 (s), 117.43 (s), 114.84 (d, J = 21.2 Hz), 111.29 (s), 105.17 (s), 51.11 (s), 24.23 (s); HRMS (ESI) m/z calcd. for C22H18FN3O [M + H]+: 360.1507, found: 360.1508.
7-((4-Isopropoxyphenyl)(6-methylpyridin-2-ylamino)methyl)quinolin-8-ol (12): white solid, yield: 25% (60 mg), m.p.: 132–134 °C, C25H25N3O2; 1H-NMR (500 MHz, DMSO) δ 9.80 (d, J = 117.5 Hz, 1H), 8.85 (dd, J = 4.1, 1.4 Hz, 1H), 8.29 (dd, J = 8.3, 1.3 Hz, 1H), 7.67 (d, J = 8.5 Hz, 1H), 7.53 (dd, J = 8.3, 4.2 Hz, 1H), 7.40 (d, J = 8.6 Hz, 1H), 7.26 (t, J = 8.2 Hz, 3H), 7.16 (d, J = 8.9 Hz, 1H), 6.82 (d, J = 8.7 Hz, 2H), 6.73 (d, J = 8.7 Hz, 1H), 6.41 (d, J = 8.3 Hz, 1H), 6.34 (d, J = 7.1 Hz, 1H), 4.53 (h, J = 6.0 Hz, 1H), 2.22 (s, 3H), 1.22 (d, J = 6.0 Hz, 6H); 13C-NMR (126 MHz, DMSO) δ 158.05 (s), 156.55 (s), 156.12 (s), 149.85 (s), 148.66 (s), 138.57 (s), 137.64(s), 136.45 (s), 135.71 (s), 128.73 (s), 127.80 (s), 127.12 (s), 126.66 (s), 122.00 (s), 117.73 (s), 115.62 (s), 111.54 (s), 105.42 (s), 69.45 (s), 51.58 (s), 24.68 (s), 22.33 (s); HRMS (ESI) m/z calcd. for C25H25N3O2 [M + H]+: 400.2020, found: 400.2018.
7-((6-Methylpyridin-2-ylamino)(pyridin-2-yl)methyl)quinolin-8-ol (13): white solid, yield: 16% (33 mg), m.p.: 170–173 °C, C21H18N4O; 1H-NMR (500 MHz, DMSO) δ 10.12 (s, 1H), 8.82 (s, 1H), 8.49 (s, 1H), 8.23 (d, J = 7.9 Hz, 1H), 7.71 (t, J = 7.1 Hz, 1H), 7.55–7.44 (m, 3H), 7.31 (d, J = 8.3 Hz, 1H), 7.27–7.18 (m, 3H), 6.76 (d, J = 7.1 Hz, 1H), 6.40 (t, J = 17.7 Hz, 1H), 6.33 (d, J = 6.7 Hz, 1H), 2.19 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 161.06 (s), 157.24 (s), 155.73 (s), 149.93 (s), 148.71 (s), 148.25 (s), 138.24 (s), 137.33 (s), 136.80 (s), 135.99 (s), 127.55 (s), 126.75 (s), 125.22 (s), 122.13 (s), 121.96 (s), 121.68 (s), 117.34 (s), 111.37 (s), 104.91 (s), 53.29 (s), 24.15 (s); HRMS (ESI) m/z calcd. for C21H18N4O [M + H]+: 343.1553, found: 343.1555.
7-(Phenyl(pyrimidin-2-ylamino)methyl)quinolin-8-ol (14): white solid, yield: 15% (30 mg), m.p.: 192–195 °C, C20H16N4O; 1H-NMR (500 MHz, DMSO) δ 9.98 (s, 1H), 8.85 (d, J = 2.9 Hz, 1H), 8.33–8.27 (m, 3H), 8.08 (d, J = 9.4 Hz, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.54 (dd, J = 8.2, 4.1 Hz, 1H), 7.44–7.36 (m, 3H), 7.28 (t, J = 7.6 Hz, 2H), 7.19 (t, J = 7.3 Hz, 1H), 7.00 (d, J = 9.4 Hz, 1H), 6.60 (t, J = 4.7 Hz, 1H); 13C-NMR (126 MHz, DMSO) δ 162.17 (s), 158.51 (s), 149.91 (s), 148.72 (s), 143.59 (s), 138.51 (s), 136.49 (s), 128.63 (s), 127.92 (s), 127.49 (s), 127.33 (s), 127.01 (s), 125.81 (s), 122.13 (s), 117.79 (s), 111.07 (s), 52.31 (s); HRMS (ESI) m/z calcd. for C20H16N4O [M + H]+: 329.1397, found: 329.1397.
7-((4-Nitrophenyl)(pyrimidin-2-ylamino)methyl)quinolin-8-ol (15): yellow solid, yield: 40% (90 mg), m.p.: 121–123 °C, C20H15N5O3; 1H-NMR (500 MHz, DMSO) δ 10.17 (s, 1H), 8.84 (d, J = 2.4 Hz, 1H), 8.29 (dd, J = 8.7, 6.1 Hz, 3H), 8.23 (d, J = 9.0 Hz, 1H), 8.15 (d, J = 8.4 Hz, 2H), 7.69 (d, J = 8.5 Hz, 1H), 7.62 (d, J = 8.4 Hz, 2H), 7.53 (dd, J = 8.0, 3.9 Hz, 1H), 7.40 (d, J = 8.5 Hz, 1H), 7.07 (d, J = 9.0 Hz, 1H), 6.62 (t, J = 4.3 Hz, 1H); 13C-NMR (126 MHz, CDCl3) δ 161.62 (s), 158.17 (s), 151.08 (s), 149.79 (s), 148.46 (s), 146.32 (s), 138.11 (s), 136.11 (s), 128.16 (s), 127.79 (s), 126.68 (s), 123.95 (s), 123.56 (s), 121.96 (s), 117.69 (s), 111.07 (s), 51.78 (s); HRMS (ESI) m/z calcd. for C20H15N5O3 [M + H]+: 374.1248, found: 374.1250.
Ethyl 4-((8-hydroxyquinolin-7-yl)(4-(trifluoromethyl)phenyl)methylamino)benzoate (16): white solid, yield: 30% (84 mg), m.p.: 95–98 °C, C26H21F3N2O3; 1H-NMR (500 MHz, DMSO) δ 10.27 (s, 1H), 8.88 (dd, J = 4.1, 1.2 Hz, 1H), 8.31 (dd, J = 8.3, 1.1 Hz, 1H), 7.72 (d, J = 8.3 Hz, 2H), 7.66 (d, J = 8.7 Hz, 2H), 7.61 (d, J = 8.2 Hz, 2H), 7.57 (dd, J = 8.3, 4.2 Hz, 1H), 7.50 (d, J = 8.6 Hz, 1H), 7.44–7.39 (m, 2H), 6.71 (d, J = 8.7 Hz, 2H), 6.35 (d, J = 7.1 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 1.24 (t, J = 7.1 Hz, 3H); 13C-NMR (126 MHz, DMSO) δ 166.21 (s), 152.16 (s), 150.63 (s), 148.95 (s), 147.18 (s), 138.58 (s), 136.59 (s), 131.27 (s), 128.63 (s), 128.30 (s), 128.12–127.65(m), 126.48 (s), 125.87 (q, J = 3.2 Hz), 124.07 (s), 122.47 (s), 118.28 (s), 117.62 (s), 112.46 (s), 60.06 (s), 54.22 (s), 14.78 (s); HRMS (ESI) m/z calcd. for C26H21F3N2O3 [M + H]+: 467.1577, found: 467.1584.
Ethyl 4-((8-hydroxyquinolin-7-yl)(pyridin-2-yl)methylamino)benzoate (17): white solid, yield: 60% (144 mg), m.p.: 157–159 °C, C24H21N3O3; 1H-NMR (500 MHz, DMSO) δ 10.22 (s, 1H), 8.84 (s, 1H), 8.54 (s, 1H), 8.23 (d, J = 8.1 Hz, 1H), 7.75 (t, J = 7.5 Hz, 1H), 7.62 (d, J = 8.0 Hz, 2H), 7.53–7.50 (m, 1H), 7.48 (d, J = 8.3 Hz, 2H), 7.42 (d, J = 6.5 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 7.28–7.22 (m, 1H), 6.73 (d, J = 7.9 Hz, 2H), 6.34 (d, J = 6.5 Hz, 1H), 4.14 (q, J = 6.8 Hz, 2H), 1.20 (t, J = 6.6 Hz, 3H); 13C-NMR (126 MHz, CDCl3) δ 165.77 (s), 159.85 (s), 151.43 (s), 150.19 (s), 148.99 (s), 148.35 (s), 138.14 (s), 137.11 (s), 136.06 (s), 130.79 (s), 127.73(s), 126.24 (s), 123.92 (s), 122.56 (s), 122.11 (s), 121.89 (s), 117.63 (s), 116.94 (s), 111.95 (s), 59.58 (s), 54.84 (s), 14.33 (s); HRMS (ESI) m/z calcd. for C24H21N3O3 [M + H]+: 400.1656, found: 400.1661.
7-(Pyridin-2-yl(4-(trifluoromethyl)phenylamino)methyl)quinolin-8-ol (18): white solid, yield: 33% (78 mg), m.p.: 162–164 °C, C22H16F3N3O; 1H-NMR (500 MHz, DMSO) δ 10.22 (s, 1H), 8.84 (d, J = 3.4 Hz, 1H), 8.55 (d, J = 4.0 Hz, 1H), 8.23 (d, J = 8.2 Hz, 1H), 7.75 (t, J = 7.5 Hz, 1H), 7.54–7.47 (m, 3H), 7.34–7.30 (m, 4H), 7.29–7.23 (m, 1H), 6.79 (d, J = 8.2 Hz, 2H), 6.31 (d, J = 6.8 Hz, 1H); 13C-NMR (126 MHz, CDCl3) δ 160.33 (s), 150.95 (s), 150.80 (s), 149.54 (s), 148.80 (s), 138.55 (s), 137.57 (s), 136.53 (s), 128.18 (s), 126.65 (s), 126.61 (s), 125.71 (q, J = 269.9 Hz), 124.33 (s), 123.01 (s), 122.57 (s), 122.33 (s), 118.10 (s), 116.35 (q, J = 31.8 Hz), 112.68 (s), 55.33 (s); HRMS (ESI) m/z calcd. for C22H16F3N3O [M + H]+: 396.1318, found: 396.1323.
7-((3-Fluoro-4-(trifluoromethyl)phenyl)(morpholino)methyl)quinolin-8-ol7-((4-nitrophenylamino) (pyridin-2-yl)methyl)quinolin-8-ol (19): yellow-green (viridian) solid, yield: 14% (31 mg), m.p.: 128–131 °C, C21H16N4O3; 1H-NMR (500 MHz, DMSO) δ 10.32 (s, 1H), 8.87–8.83 (m, 1H), 8.57 (d, J = 3.1 Hz, 1H), 8.25 (d, J = 8.2 Hz, 1H), 8.12 (d, J = 6.6 Hz, 1H), 7.94 (d, J = 8.6 Hz, 2H), 7.77 (t, J = 7.6 Hz, 1H), 7.53 (dd, J = 7.8, 3.8 Hz, 1H), 7.50–7.41 (m, 2H), 7.34 (d, J = 8.5 Hz, 1H), 7.31–7.25 (m, 1H), 6.78 (bs, 2H), 6.39 (d, J = 6.7 Hz, 1H); 13C-NMR (126 MHz, CDCl3) δ 159.21 (s), 153.27 (s), 150.30 (s), 149.11 (s), 148.46 (s), 138.14 (s), 137.25 (s), 136.43 (s), 136.11 (s), 127.87 (s), 126.09 (s), 126.03 (s), 123.23 (s), 122.76 (s), 122.21 (s), 122.03 (s), 117.77 (s), 55.15 (s); HRMS (ESI) m/z calcd. for C21H16N4O3 [M + H]+: 373.1295, found: 373.1299.
7-((6-Methylpyridin-2-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (20): white solid, yield: 33% (81 mg), m.p.: 147–150 °C, C23H18F3N3O; 1H-NMR (500 MHz, DMSO) δ 10.06 (s, 1H), 8.83 (bs, 1H), 8.27 (d, J = 8.0 Hz, 1H), 7.66–7.59 (m, 3H), 7.56 (d, J = 7.4 Hz, 2H), 7.52 (d, J = 2.7 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.26 (t, J = 7.1 Hz, 1H), 6.93 (d, J = 8.1 Hz, 1H), 6.46 (d, J = 8.0 Hz, 1H), 6.35 (d, J = 6.6 Hz, 1H), 2.19 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 157.41 (s), 155.70 (s), 149.70 (s), 148.68 (s), 148.38 (s), 138.15 (s), 137.27 (s), 136.07 (s), 127.79 (s), 127.62 (s), 127.16 (q, J = 31.7 Hz), 126.67 (s), 125.11 (dd, J = 6.9, 3.8 Hz), 124.96 (s), 124.39 (q, J = 271.7 Hz), 121.81 (s), 117.57 (s), 111.44 (s), 105.41 (s), 52.20 (s), 24.24 (s); HRMS (ESI) m/z calcd. for C23H18F3N3O [M + H]+: 410.1475, found: 410.1478.
7-((6-Methylpyridin-2-ylamino)(4-nitrophenyl)methyl)quinolin-8-ol (21): pale yellow solid, yield: 51% (118 mg), m.p.: 159–161 °C, C22H18N4O3; 1H-NMR (500 MHz, DMSO) δ 10.13 (s, 1H), 8.84 (d, J = 2.8 Hz, 1H), 8.28 (d, J = 8.1 Hz, 1H), 8.15 (d, J = 8.5 Hz, 2H), 7.64–7.56 (m, 3H), 7.53 (dd, J = 8.1, 4.0 Hz, 1H), 7.40 (t, J = 8.4 Hz, 2H), 7.33–7.19 (m, 1H), 6.96 (d, J = 8.3 Hz, 1H), 6.47 (d, J = 8.2 Hz, 1H), 6.36 (d, J = 7.1 Hz, 1H), 2.19 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 157.28 (s), 155.70 (s), 151.99 (s), 149.79 (s), 148.45 (s), 146.17 (s), 138.16 (s), 137.30 (s), 136.10 (s), 128.14 (s), 127.72 (s), 126.66 (s), 124.48 (s), 123.48 (s), 121.92 (s), 117.67 (s), 111.56 (s), 105.57 (s), 51.47 (s), 24.24 (s); HRMS (ESI) m/z calcd. for C22H18N4O3 [M + H]+: 387.1452, found: 387.1451.
2-Methyl-7-((6-methylpyridin-2-ylamino)(4-nitrophenyl)methyl)quinolin-8-ol (22): ivory-white solid, yield: 23% (55 mg), m.p.: 134–136 °C, C23H20N4O3; 1H-NMR (500 MHz, DMSO) δ 9.64 (s, 1H), 8.20–8.10 (m, 3H), 7.62 (d, J = 8.7 Hz, 2H), 7.53 (d, J = 8.5 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.41 (d, J = 8.6 Hz, 1H), 7.37 (d, J = 8.5 Hz, 1H), 7.30 (dd, J = 8.0, 7.4 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 6.50 (d, J = 8.3 Hz, H), 6.39 (d, J = 7.2 Hz, 1 H), 2.69 (d, J = 10.1 Hz, 3H), 2.22 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 157.73 (s), 157.60 (s), 156.12 (s), 152.53 (s), 149.34 (s), 146.59 (s), 137.87 (s), 137.74 (s), 136.58 (s), 128.52 (s), 126.23 (s), 125.95 (s), 124.69 (s), 123.91 (s), 123.17 (s), 117.96 (s), 111.99 (s), 106.04 (s), 51.87 (s), 25.16 (s), 24.69 (s); HRMS (ESI) m/z calcd. for C23H20N4O3 [M + H]+: 401.1608, found: 401.1609.
2-Methyl-7-((6-methylpyridin-2-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (23): beige solid, yield: 71% (180 mg), m.p.: 122–124 °C, C24H20F3N3O; 1H-NMR (500 MHz, DMSO) δ 9.54 (s, 1H), 8.15 (d, J = 8.4 Hz, 1H), 7.82 (d, J = 3.9 Hz, 1H), 7.65–7.59 (m, 3H), 7.55 (d, J = 7.9 Hz, 2H), 7.39 (d, J = 8.4 Hz, 1H), 7.33 (d, J = 8.5 Hz, 1H), 7.27 (d, J = 6.7 Hz, 1H), 7.07 (t, J = 18.0 Hz, 1H), 6.54–6.43 (m, 2H), 2.67 (s, 3H), 2.19 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 157.02 (s), 155.79 (s), 149.05 (s), 148.68 (s), 144.77 (s), 137.48 (s), 136.92 (s), 136.10 (s), 127.85 (s), 127.08 (dd, J = 63.3, 31.6 Hz), 126.25 (s), 125.75 (s), 124.97 (dd, J = 6.8, 3.8 Hz), 124.64 (s), 124.42 (q, J = 271.9 Hz), 122.59 (s), 117.34 (s), 117.14 (s), 112.75 (s), 52.45 (s), 24.69 (s), 16.92 (s); HRMS (ESI) m/z calcd. for C24H20F3N3O [M + H]+: 424.1631, found: 424.1631.
7-((6-Methylpyridin-2-ylamino)(4-(trifluoromethoxy)phenyl)methyl)quinolin-8-ol (24): white solid, yield: 34% (87 mg), m.p.: 99–101 °C, C23H18F3N3O2; 1H-NMR (500 MHz, DMSO) δ 10.00 (s, 1H), 8.82 (d, J = 2.0 Hz, 1H), 8.27 (d, J = 8.1 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.51 (dd, J = 7.6, 3.6 Hz, 1H), 7.45 (d, J = 8.1 Hz, 2H), 7.39 (d, J = 8.4 Hz, 1H), 7.30 (d, J = 8.6 Hz, 1H), 7.28–7.21 (m, 3H), 6.86 (d, J = 8.2 Hz, 1H), 6.43 (d, J = 8.1 Hz, 1H), 6.34 (d, J = 6.9 Hz, 1H), 2.19 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 157.44 (s), 155.70 (s), 149.71 (s), 148.31 (s), 146.90 (s), 143.21 (s), 138.17 (s), 137.25 (s), 136.05 (s), 128.89 (s), 127.57 (s), 126.57 (s), 125.30 (s), 121.73 (s), 120.78 (s), 117.42 (s), 116.02 (d, J = 260.6 Hz), 111.35 (s), 105.28 (s), 51.14 (s), 24.24 (s); HRMS (ESI) m/z calcd. for C23H18F3N3O2 [M + H]+: 426.1424, found: 426.1423.
7-((6-Methylpyridin-2-ylamino)(3-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (25): white solid, yield: 62% (152 mg), m.p.: 148–152 °C, C23H18F3N3O; 1H-NMR (500 MHz, DMSO) δ 10.07 (s, 1H), 8.83 (s, 1H), 8.27 (d, J = 8.2 Hz, 1H), 7.71 (s, 1H), 7.69–7.60 (m, 2H), 7.56–7.46 (m, 3H), 7.44–7.35 (m, 2H), 7.27 (t, J = 7.6 Hz, 1H), 6.93 (d, J = 8.6 Hz, 1H), 6.45 (d, J = 8.2 Hz, 1H), 6.35 (d, J = 6.9 Hz, 1H), 2.19 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 157.37 (s), 155.70 (s), 149.67 (s), 148.41 (s), 145.29 (s), 138.12 (s), 137.32 (s), 136.08 (s), 131.32 (s), 129.29 (s), 128.88 (d, J = 31.4 Hz), 127.60 (s), 126.44 (s), 125.22 (q, J = 48.0 Hz), 125.03 (s), 123.34 (s), 121.82 (s), 117.62 (s), 111.49 (s), 105.40 (s), 51.40 (s), 24.21 (s); HRMS (ESI) m/z calcd. for C23H18F3N3O [M + H]+: 410.1475, found: 410.1476.
7-((3-Methylpyridin-2-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (26): white solid, yield: 18% (44 mg), m.p.: 148–151 °C, C23H18F3N3O; 1H-NMR (500 MHz, DMSO) δ 10.09 (s, 1H), 8.83 (d, J = 3.1 Hz, 1H), 8.28 (d, J = 8.2 Hz, 1H), 7.81 (d, J = 4.1 Hz, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 7.9 Hz, 2 H), 7.58–7.48 (m, 3H), 7.39 (d, J = 8.4 Hz, 1H), 7.27 (d, J = 6.7 Hz, 1H), 7.11 (d, J = 8.1 Hz, 1H), 6.53–6.45 (m, 2H), 2.19 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 155.75 (s), 149.93 (s), 148.57 (s), 148.34 (s), 144.73 (s), 138.18 (s), 136.95 (s), 136.06 (s), 127.93 (s), 127.67 (s), 127.32 (s), 127.10 (q, J = 31.3 Hz), 125.00 (q, J = 2.9 Hz), 124.88 (s), 124.42 (q, J = 272.0 Hz), 121.79 (s), 117.48 (s), 117.17 (s), 112.75 (s), 52.33 (s), 16.95 (s); HRMS (ESI) m/z calcd. for C23H18F3N3O [M + H]+: 410.1475, found: 410.1479.
7-((4-Methylpyridin-2-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (27): mulatto solid, yield: 15% (37 mg), m.p.: 151–153 °C, C23H18F3N3O; 1H-NMR (500 MHz, DMSO) δ 10.06 (s, 1H), 8.86 (dd, J = 4.1, 1.4 Hz, 1H), 8.30 (dd, J = 8.3, 1.3 Hz, 1H), 7.80 (d, J = 5.2 Hz, 1H), 7.66 (d, J = 8.2 Hz, 2H), 7.59 (d, J = 8.5 Hz, 1H), 7.57–7.53 (m, 3H), 7.42 (d, J = 8.6 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 6.54 (s, 1H), 6.36 (d, J = 5.1 Hz, 1H), 2.15 (s, H); 13C-NMR (126 MHz, DMSO) δ 158.49 (s), 150.16 (s), 149.13 (s), 148.81 (s), 147.58 (s), 147.46 (s), 138.59 (s), 136.52 (s), 128.27 (s), 128.05 (s), 127.60 (q, J = 31.5 Hz), 127.03 (s), 125.58(q, J = 3.5 Hz), 125.49 (s), 124.83 (q, J = 271.6 Hz), 122.24 (s), 117.96 (s), 114.48 (s), 109.35 (s), 51.91 (s), 21.09 (s); HRMS (ESI) m/z calcd. for C23H18F3N3O [M + H]+: 410.1475, found: 410.1477.
7-((3-Fluoro-5-(trifluoromethyl)phenyl)(6-methylpyridin-2-ylamino)methyl)quinolin-8-ol (28): white solid, yield: 35% (90 mg), m.p.: 163–165 °C, C23H17F4N3O; 1H-NMR (500 MHz, DMSO) δ 10.19 (s, 1H), 8.87 (dd, J = 4.0, 1.2 Hz, 1H), 8.31 (dd, J = 8.3, 1.1 Hz, 1H), 7.67 (d, J = 8.6 Hz, 1H), 7.60 (s, 1H), 7.56 (dd, J = 8.3, 4.2 Hz, 1H), 7.51 (d, J = 9.2 Hz, 2H), 7.45 (d, J = 8.4 Hz, 2H), 7.31 (t, J = 7.7 Hz, 1H), 6.95 (d, J = 8.7 Hz, 1H), 6.50 (d, J = 8.3 Hz, 1H), 6.40 (d, J = 7.2 Hz, 1H), 2.22 (s, 3H); 13C NMR (126 MHz, DMSO) δ 162.40 (d, J = 246.4 Hz), 157.62 (s), 156.15 (s), 150.19 (s), 149.34 (d, J = 6.8 Hz), 148.95 (s), 138.57 (s), 137.84 (s), 136.57 (s), 131.17 (qd, J = 32.7, 8.7 Hz), 128.16 (s), 126.69 (s), 124.86 (s), 123.82 (dq, J = 272.8, 2.6 Hz), 122.40 (s), 120.30–120.02 (m), 118.39 (d, J = 21.8 Hz), 118.22 (s), 112.16 (s), 111.39 (dq, J = 25.1, 3.4 Hz), 106.01 (s), 51.75 (s), 24.64 (s); HRMS (ESI) m/z calcd. for C23H17F4N3O [M + H]+: 428.1381, found: 428.1388.
7-((3,5-bis(Trifluoromethyl)phenyl)(6-methylpyridin-2-ylamino)methyl)quinolin-8-ol (29): white solid, yield: 43% (123 mg), m.p.: 144–146 °C, C24H17F6N3O; 1H-NMR (500 MHz, DMSO) δ 10.20 (s, 1H), 8.84 (bs, 1H), 8.28 (d, J = 8.1 Hz, 1H), 8.03 (s, 2H), 7.92 (s, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.58–7.48 (m, 2H), 7.43 (d, J = 8.4 Hz, 1H), 7.29 (t, J = 7.6 Hz, 1H), 6.98 (d, J = 8.3 Hz, 1H), 6.48 (d, J = 8.1 Hz, 1H), 6.38 (d, J = 6.9 Hz, 1H), 2.19 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 157.12 (s), 155.69 (s), 149.81 (s), 148.56 (s), 147.44 (s), 138.11 (s), 137.44 (s), 136.13 (s), 130.08 (q, J = 32.3 Hz), 127.78 (s), 127.68 (s), 126.08 (s), 124.14 (s), 123.39 (q, J = 272.5 Hz), 122.01 (s), 120.48 (s), 117.87 (s), 111.83 (s), 105.67 (s), 51.55 (s), 24.13 (s); HRMS (ESI) m/z calcd. for C24H17F6N3O [M + H]+: 478.1349, found: 478.1353.
7-((4-Fluoro-3-(trifluoromethyl)phenyl)(6-methylpyridin-2-ylamino)methyl)quinolin-8-ol (30): white solid, yield: 90% (231 mg), m.p.: 148–151 °C, C23H17F4N3O; 1H-NMR (500 MHz, DMSO) δ 10.10 (s, 1H), 8.83 (s, 1H), 8.27 (d, J = 8.1 Hz, 1H), 7.73 (d, J = 6.2 Hz, 1H), 7.65 (d, J = 8.7 Hz, 2H), 7.52 (dd, J = 8.0, 3.9 Hz, 1H), 7.45–7.36 (m, 3H), 7.27 (t, J = 7.7 Hz, 1H), 6.87 (d, J = 8.5 Hz, 1H), 6.44 (t, J = 9.4 Hz, 1H), 6.34 (t, J = 15.0 Hz, 1H), 2.19 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 159.53–156.77 (m), 157.71 (s), 156.16 (s), 150.13 (s), 148.90 (s), 141.39 (d, J = 3.4 Hz), 138.55 (s), 137.76 (d, J = 13.0 Hz), 136.55 (s), 134.27 (d, J = 8.5 Hz), 129.47–121.35 (m), 128.10(s), 126.68 (s), 125.77 (q, J = 4.7 Hz), 125.26 (s), 122.31 (s), 118.12 (s), 117.48 (d, J = 20.4 Hz), 116.78–116.78 (m), 112.03 (s), 105.88 (s), 51.42 (s), 24.65 (s); HRMS (ESI) m/z calcd. for C23H17F4N3O [M + H]+: 428.1381, found: 428.1385.
7-((2,4-bis(Trifluoromethyl)phenyl)(6-methylpyridin-2-ylamino)methyl)quinolin-8-ol (31): light rose solid, yield: 22% (63 mg), m.p.: decomposed 230 °C, C24H17F6N3O; 1H-NMR (500 MHz, DMSO) δ 9.83 (s, 1H), 8.87 (d, J = 2.9 Hz, 1H), 8.33 (d, J = 8.0 Hz, 1H), 8.16 (d, J = 8.2 Hz, 1H), 8.11 (d, J = 8.2 Hz, 1H), 8.01 (s, 1H), 7.63 (dd, J = 8.6, 4.1 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.25 (t, J = 7.7 Hz, 1H), 6.92 (d, J = 8.0 Hz, 1H), 6.63 (d, J = 8.0 Hz, 1H), 6.37 (d, J = 7.2 Hz, 1H), 2.17 (s, 3H); HRMS (ESI) m/z calcd. for C24H17F6N3O [M + H]+: 478.1349, found: 478.1356.
7-((3,4-Difluorophenyl)(6-methylpyridin-2-ylamino)methyl)quinolin-8-ol (32): white solid, yield: 53% (120 mg), m.p.: 175–178 °C, C22H17F2N3O; 1H-NMR (500 MHz, DMSO) δ 10.10 (s, 1H), 8.86 (dd, J = 4.0, 1.2 Hz, 1H), 8.30 (dd, J = 8.2, 1.1 Hz, 1H), 7.63 (d, J = 8.5 Hz, 1H), 7.55 (dd, J = 8.3, 4.2 Hz, 1H), 7.42 (d, J = 8.6 Hz, 1H), 7.40–7.27 (m, 4 H), 7.24–7.15 (m, 1H), 6.83 (d, J = 8.8 Hz, 1H), 6.46 (d, J = 8.3 Hz, 1H), 6.38 (d, J = 7.2 Hz, 1H), 2.26 (d, J = 40.6 Hz, 3H); 13C-NMR (126 MHz, CDCl3) δ 157.32 (s), 155.72 (s), 149.61 (s), 149.19 (dd, J = 245.7, 13.0 Hz), 148.38 (s), 148.09 (dd, J = 244.0, 13.1 Hz), 141.68 (s), 138.14 (s), 137.30 (s), 136.07 (s),127.59 (s), 126.43 (s), 125.08 (s), 123.70 (s), 121.80 (s), 117.58 (s), 117.16 (d, J = 16.9 Hz), 115.74 (d, J = 17.3 Hz), 111.50 (s), 105.33 (s), 50.96 (s), 24.22 (s); HRMS (ESI) m/z calcd. for C22H17F2N3O [M + H]+: 378.1412, found: 378.1413.
7-((Pyrimidin-2-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (33): white solid, yield: 32% (76 mg), m.p.: 160–163 °C, C21H15F3N4O; 1H-NMR (500 MHz, DMSO) δ 10.10 (s, 1H), 8.83 (d, J = 2.3 Hz, 1H), 8.33–8.23 (m, 3H), 8.18 (d, J = 9.1 Hz, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.64 (d, J = 7.9 Hz, 2H), 7.57 (d, J = 7.8 Hz, 2H), 7.52 (dd, J = 8.0, 3.9 Hz, 1H), 7.39 (d, J = 8.5 Hz, 1H), 7.04 (d, J = 9.1 Hz, 1H), 6.60 (t, J = 4.3 Hz, 1H); 13C-NMR (126 MHz, CDCl3) δ 162.48 (s), 158.95 (s), 150.50 (s), 149.22 (s), 148.76 (s), 138.91 (s), 136.90 (s), 128.58 (s), 128.51 (s), 128.14 (q, J = 31.7 Hz), 127.53 (s), 126.01 (q, J = 3.7 Hz), 125.23 (s), 125.17 (q, J = 272.1 Hz), 122.68 (s), 118.42 (s), 111.75 (s), 52.59 (s); HRMS (ESI) m/z calcd. for C21H15F3N4O [M + H]+: 397.1271, found: 397.1273.
7-((4-Methylpyrimidin-2-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (34): white solid, yield: 46% (113 mg), m.p.: 147–149 °C, C22H17F3N4O; 1H-NMR (500 MHz, DMSO) δ 10.12 (s, 1H), 8.86 (dd, J = 4.1, 1.5 Hz, 1H), 8.31 (dd, J = 8.3, 1.3 Hz, 1H), 8.16 (d, J = 5.0 Hz, 1H), 8.11 (d, J = 9.4 Hz, 1H), 7.75 (d, J = 8.6 Hz, 1H), 7.66 (d, J = 8.3 Hz, 2H), 7.60 (d, J = 8.2 Hz, 2H), 7.55 (dd, J = 8.3, 4.2 Hz, 1H), 7.42 (d, J = 8.6 Hz, 1H), 7.09 (d, J = 9.4 Hz, 1H), 6.52 (d, J = 5.0 Hz, 1H), 2.26 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 167.94 (s), 162.02 (s), 158.11 (s), 150.04 (s), 148.83 (s), 148.65 (s), 138.53 (s), 136.53 (s), 128.15 (s), 128.10 (s), 127.67 (q, J = 31.5 Hz), 127.22 (s), 125.61 (q, J = 3.5 Hz), 125.01 (s), 124.81 (q, J = 271.6 Hz), 122.29 (s), 118.03 (s), 110.84 (s), 52.09 (s), 24.11 (s).
7-((4-Methylpyrimidin-2-ylamino)(4-nitrophenyl)methyl)quinolin-8-ol (35): white solid, yield: 19% (44 mg), m.p.: 136–138 °C, C21H17N5O3; 1H-NMR (500 MHz, DMSO) δ 10.15 (s, 1H), 8.84 (d, J = 2.5 Hz, 1H), 8.28 (d, J = 7.9 Hz, 1H), 8.18–8.09 (m, 4H), 7.71 (d, J = 8.5 Hz, 1H), 7.62 (d, J = 8.4 Hz, 2H), 7.53 (dd, J = 8.1, 4.0 Hz, 1H), 7.40 (d, J = 8.5 Hz, 1H), 7.09 (d, J = 9.2 Hz, 1H), 6.51 (d, J = 4.8 Hz, 1H), 2.24 (s, 3 H); 13C-NMR (126 MHz, CDCl3) δ 168.00 (s), 161.51 (s), 158.09 (s), 151.33 (s), 149.69 (s), 148.45 (s), 146.26 (s), 138.10 (s), 136.10 (s), 128.10 (s), 127.75 (s), 126.73 (s), 124.09 (s), 123.53 (s), 121.94 (s), 117.68 (s), 110.53 (s), 51.69 (s), 23.69 (s); HRMS (ESI) m/z calcd. for C21H17N5O3 [M + H]+: 388.1404, found: 388.1409.
7-((4-Methylpyrimidin-2-ylamino)(4-(pentafluorothio)phenyl)methyl)quinolin-8-ol (36): white solid, yield: 68% (191 mg), m.p.: 164–165 °C, C21H17F5N4OS; 1H-NMR (500 MHz, DMSO) δ 10.16 (s, 1H), 8.87 (dd, J = 4.1, 1.5 Hz, 1H), 8.31 (dd, J = 8.3, 1.5 Hz, 1H), 8.17 (d, J = 5.0 Hz, 1H), 8.12 (d, J = 9.4 Hz, 1H), 7.84 (d, J = 8.9 Hz, 2H), 7.75 (d, J = 8.6 Hz, 1H), 7.59 (d, J = 8.5 Hz, 2H), 7.55 (dt, J = 12.4, 6.2 Hz, 1H), 7.43 (d, J = 8.6 Hz, 1H), 7.07 (d, J = 9.4 Hz, 1H), 6.52 (t, J = 6.2 Hz, 1H), 2.26 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 168.2–167.74 (m), 161.98 (s), 158.28–157.83 (m), 152.05–151.32 (m), 150.08 (s), 148.86 (s), 148.60 (s), 138.53 (s), 136.54 (s), 128.25(s), 128.16 (s), 127.13 (s), 126.36–126.19 (m), 124.73 (s), 122.34 (s), 118.09 (s), 110.92 (s), 51.90 (s), 24.11 (s); HRMS (ESI) m/z calcd. for C21H17F5N4OS [M + H]+: 469.1116, found: 469.1118.
7-((4-Fluorophenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (37): white solid, yield: 16% (35 mg), m.p.: 156–158 °C, C21H17FN4O; 1H-NMR (500 MHz, DMSO) δ 9.97 (s, 1H), 8.82 (d, J = 2.8 Hz, 1H), 8.27 (d, J = 8.2 Hz, 1H), 8.12 (d, J = 4.9 Hz, 1H), 7.98 (d, J = 9.5 Hz, 1H), 7.74 (d, J = 8.5 Hz, 1H), 7.51 (dd, J = 8.2, 4.1 Hz, 1H), 7.42–7.31 (m, 3H), 7.12–7.03 (m, 2H), 6.98 (t, J = 12.1 Hz, 1H), 6.47 (d, J = 4.9 Hz, 1H), 2.22 (s, H); 13C-NMR (126 MHz, CDCl3) δ 167.90 (s), 161.58 (s), 158.06 (s), 160.95 (d, J = 242.0 Hz), 149.37 (s), 148.30 (s), 139.53 (s), 138.07 (s), 136.05 (s), 128.87 (d, J = 8.1 Hz), 127.51 (s), 126.74 (s), 125.34 (s), 121.71 (s), 117.43 (s), 114.85 (d, J = 21.2 Hz), 110.20 (s), 51.25 (s), 23.63 (s); HRMS (ESI) m/z calcd. for C21H17FN4O [M + H]+: 361.1459, found: 361.1460.
7-((4-Iodophenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (38): white solid, yield: 18% (51 mg), m.p.: 139–142 °C, C21H17IN4O; 1H-NMR (500 MHz, DMSO) δ 9.99 (s, 1 H), 8.82 (s, 1 H), 8.27 (d, J = 8.2 Hz, 1 H), 8.12 (d, J = 4.3 Hz, 1 H), 7.96 (d, J = 9.3 Hz, 1 H), 7.70 (d, J = 8.4 Hz, 1 H), 7.61 (d, J = 7.8 Hz, 2 H), 7.52 (dd, J = 7.8, 3.8 Hz, 1 H), 7.37 (d, J = 8.4 Hz, 1 H), 7.15 (d, J = 7.6 Hz, 2 H), 6.91 (d, J = 9.3 Hz, 1 H), 6.48 (d, J = 4.5 Hz, 1 H), 2.22 (s, 3 H) 13C-NMR (126 MHz, DMSO) δ 167.89 (s), 162.01 (s), 158.01 (s), 149.90 (s), 148.77 (s), 143.75 (s), 138.51 (s), 137.34 (s), 136.50 (s), 129.86 (s), 128.00 (s), 127.23 (s), 125.35 (s), 122.20 (s), 117.91 (s), 110.69 (s), 92.81 (s), 51.91 (s), 24.06 (s); HRMS (ESI) m/z calcd. for C21H17IN4O [M + H]+: 469.0520, found: 469.0525.
7-((4-Bromophenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (39): ivory-white solid, yield: 29% (73 mg), m.p.: 143–145 °C, C21H17BrN4O; 1H-NMR (500 MHz, DMSO) δ 10.00 (s, 1H), 8.82 (s, 1H), 8.27 (d, J = 7.9 Hz, 1H), 8.12 (d, J = 4.5 Hz, 1H), 7.98 (d, J = 9.2 Hz, 1H), 7.71 (d, J = 8.5 Hz, 1H), 7.52 (dd, J = 7.8, 3.8 Hz, 1H), 7.44 (d, J = 8.1 Hz, 2H), 7.38 (d, J = 8.4 Hz, 1H), 7.30 (d, J = 8.0 Hz, 2H), 6.94 (d, J = 9.3 Hz, 1H), 6.48 (d, J = 4.6 Hz, 1H), 2.22 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 167.85 (s), 161.57 (s), 149.46 (s), 148.34 (s), 142.86 (s), 138.07 (s), 136.06 (s), 131.04 (s), 129.24 (s), 127.57 (s), 126.77 (s), 124.91 (s), 121.77 (s), 119.59 (s), 117.48 (s), 110.27 (s), 51.39 (s), 24.39 (s); HRMS (ESI) m/z calcd. for C21H17BrN4O [M + H]+: 421.0659, found: 421.0664.
7-((4-Chlorophenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (40): white solid, yield: 40% (90 mg), m.p.: 139–141 °C, C21H17ClN4O; 1H-NMR (500 MHz, DMSO) δ 10.04 (s, 1H), 8.86 (dd, J = 3.9, 1.3 Hz, 1H), 8.30 (d, J = 8.3 Hz, 1H), 8.15 (d, J = 4.9 Hz, 1H), 8.02 (d, J = 9.4 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.55 (dd, J = 8.2, 4.1 Hz, 1H), 7.44–7.37 (m, 3H), 7.34 (d, J = 8.5 Hz, 2H), 6.98 (d, J = 9.4 Hz, 1H), 6.51 (d, J = 5.0 Hz, 1H), 2.25 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 167.90 (s), 162.01 (s), 158.05 (s), 149.90 (s), 148.78 (s), 142.86 (s), 138.51 (s), 136.51 (s), 131.53 (s), 129.29 (s), 128.57 (s), 128.00 (s), 127.19 (s), 125.43 (s), 122.21 (s), 117.92 (s), 110.70 (s), 51.74 (s), 24.09 (s); HRMS (ESI) m/z calcd. for C21H17ClN4O [M + H]+: 377.1164, found: 377.1167.
7-((4-Methylpyrimidin-2-ylamino)(3-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (41): white solid, yield: 31% (76 mg), m.p.: 160–163 °C, C22H17F3N4O; 1H-NMR (500 MHz, DMSO) δ 10.08 (s, 1H), 8.91–8.73 (m, 1H), 8.27 (d, J = 8.2 Hz, 1H), 8.21–8.06 (m, 2H), 7.81–7.70 (m, 2H), 7.67 (d, J = 7.0 Hz, 1H), 7.59–7.44 (m, 3H), 7.40 (d, J = 8.5 Hz, 1H), 7.07 (d, J = 9.4 Hz, 1H), 6.49 (d, J= 4.7 Hz, 1H), 2.23 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 168.00 (s), 161.96 (s), 149.96 (s), 148.87 (s), 145.32 (s), 138.50 (s), 136.54 (s), 131.70 (s), 129.79 (s), 129.36 (q, J = 31.4 Hz), 128.07 (s), 126.93 (s), 125.18 (s), 124.74 (q, J = 272.43 Hz), 123.87 (q, J = 3.6 Hz), 123.68 (q, J = 3.7 Hz), 122.30 (s), 118.09 (s), 110.85 (s), 51.95 (s), 24.16 (s); HRMS (ESI) m/z calcd. for C22H17F3N4O [M + H]+: 411.1427, found: 411.1428.
7-((3,5-bis(Trifluoromethyl)phenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (42): white solid, yield: 59% (169 mg), m.p.: 128–130 °C, C23H16F6N4O; 1H-NMR (500 MHz, DMSO) δ 10.24 (s, 1H), 8.84 (d, J = 2.8 Hz, 1H), 8.36–8.23 (m, 2H), 8.15 (d, J = 4.8 Hz, 1H), 8.08 (s, 2H), 7.93 (s, 1H), 7.77 (d, J = 8.5 Hz, 1H), 7.53 (dd, J = 8.2, 4.1 Hz, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.13 (d, J = 9.4 Hz, 1H), 6.52 (d, J = 4.9 Hz, 1H), 2.24 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 167.63 (s), 161.38 (s), 157.64 (s), 149.65 (s), 148.57 (s), 146.83 (s), 138.06 (s), 136.14 (s), 130.19 (q, J = 32.9 Hz), 127.80 (s), 127.63 (s), 125.96 (s), 123.97 (s), 123.35 (q, J = 272.8 Hz), 122.02 (s), 120.80–120.55 (m), 117.93 (s), 110.72 (s), 51.60 (s), 23.62 (s); HRMS (ESI) m/z calcd. for C23H16F6N4O [M + H]+: 479.1301, found: 479.1304.
7-((2,4-bis(Trifluoromethyl)phenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (43): white solid, yield: 16% (46 mg), m.p.: 199–201 °C, C23H16F6N4O; 1H-NMR (500 MHz, DMSO) δ 9.97 (s, 1H), 8.81 (d, J = 2.4 Hz, 1H), 8.28 (d, J = 7.8 Hz, 1H), 8.08 (s, 1H), 8.03 (d, J = 6.0 Hz, 1H), 7.99–7.95 (m, 2H), 7.80 (bs, 1H), 7.52 (dd, J = 8.1, 3.9 Hz, 1H), 7.33 (dd, J = 11.7, 9.2 Hz, 2H), 7.21 (d, J = 4.7 Hz, 1H), 6.47 (d, J = 4.7 Hz, 1H), 2.19 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 169.04 (s), 161.45 (s), 158.49 (s), 150.79 (s), 148.79 (s), 138.45 (s), 136.53 (s), 131.63 (s), 129.90–129.72 (m), 128.66 (q, J = 31.4 Hz), 128.55 (q, J = 32.7 Hz), 128.26 (s), 127.05–126.81 (m), 124.01 (q, J = 275.4 Hz), 123.97 (q, J = 272.2 Hz), 123.57–123.27 (m), 122.34 (s), 117.30 (s), 116.90 (s), 110.80 (s), 49.76 (s), 24.05 (s); HRMS (ESI) m/z calcd. for C23H16F6N4O [M + H]+: 479.1301, found: 479.1307.
7-((4-Fluoro-3-(trifluoromethyl)phenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (44): white solid, yield: 25% (64 mg), m.p.: 89–92 °C, C22H16F4N4O; 1H-NMR (500 MHz, DMSO) δ 10.10 (s, 1H), 8.82 (bs, 1H), 8.26 (d, J = 5.6 Hz, 1H), 8.19–8.08 (m, 2H), 7.83–7.64 (m, 3H), 7.51 (dd, J = 5.6, 3.6 Hz, 1 H), 7.43–7.31 (m, 2H), 7.01 (d, J = 7.7 Hz, 1H), 6.49 (bs, 1H), 2.22 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 167.49 (bs), 161.44 (s), 157.95–157.18 (m), 157.63 (d, J = 252.6 Hz), 149.50 (s), 148.44 (s), 140.49 (s), 138.05 (s), 136.09 (s), 133.81 (d, J = 8.5 Hz), 127.67 (s), 126.23 (s), 125.27 (d, J = 3.4 Hz), 124.56 (s), 123.77 (s), 121.87 (s), 117.70 (s), 117.08 (d, J = 20.5 Hz), 110.49 (s), 51.15 (s), 23.62 (s); HRMS (ESI) m/z calcd. for C22H16F4N4O [M + H]+: 429.1333, found: 429.1337.
7-((3-Fluoro-5-(trifluoromethyl)phenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (45): ivory-white solid, yield: 15% (39 mg), m.p.: decomposed 92 °C, C22H16F4N4O; 1H-NMR (500 MHz, DMSO) δ 10.22 (s, 1H), 8.87 (d, J = 3.0 Hz, 1H), 8.31 (d, J = 8.1 Hz, 1H), 8.21 (d, J = 9.5 Hz, 1H), 8.18 (d, J = 4.8 Hz, 1H), 7.77 (d, J = 8.5 Hz, 1H), 7.65 (s, 1H), 7.58–7.52 (m, 3H), 7.44 (d, J = 8.5 Hz, 1H), 7.09 (d, J = 9.4 Hz, 1H), 6.55 (d, J = 4.9 Hz, 1H), 2.27 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 162.39 (d, J = 246.5 Hz), 161.86 (s), 150.03 (s), 148.97 (s), 148.74 (d, J = 6.8 Hz), 138.51 (s), 136.57 (s), 131.72–131.06 (m), 128.19 (s), 126.64 (s), 124.61 (s), 123.80 (dq, J = 272.7, 4.2 Hz), 122.42 (s), 120.28–119.83 (m), 118.40 (d, J = 22.0 Hz), 118.26 (s), 111.74–111.36 (m), 111.08 (s), 51.86 (s), 24.10 (s); HRMS (ESI) m/z calcd. for C22H16F4N4O [M + H]+: 429.1333, found: 429.1336.
7-((5-Bromopyrimidin-2-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (46): white solid, yield: 15% (43 mg), m.p.: 146–148 °C, C21H14BrF3N4O; 1H-NMR (500 MHz, DMSO) δ 10.12 (s, 1H), 8.84 (d, J = 2.2 Hz, 1H), 8.50 (d, J = 8.9 Hz, 1H), 8.41 (s, 2H), 8.28 (d, J = 7.9 Hz, 1H), 7.70–7.61 (m, 3H), 7.59–7.49 (m, 3H), 7.39 (d, J = 8.4 Hz, 1H), 6.96 (d, J = 8.8 Hz, 1H); 13C-NMR (126 MHz, CDCl3) δ 160.07 (s), 149.81 (s), 148.45 (s), 147.38 (s), 138.07 (s), 136.11 (s), 127.82 (s), 127.75 (s), 127.19 (q, J = 31.8 Hz), 126.52 (s), 125.26 (q, J = 4.0 Hz), 124.77 (q, J = 272.0 Hz), 123.91 (s), 121.93 (s), 117.62 (s), 106.09 (s), 52.12 (s); HRMS (ESI) m/z calcd. for C21H14BrF3N4O [M + H]+: 475.0376, found: 475.0384.
7-((2-Hydroxyphenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (47): caesious solid, yield: 15% (32 mg), m.p.: decomposed 179 °C, C21H18N4O2; 1H-NMR (500 MHz, DMSO) δ 9.81 (s, 1 H), 9.49 (s, 1 H), 8.82 (d, J = 2.9 Hz, 1 H), 8.28 (d, J = 7.7 Hz, 1 H), 8.11 (d, J = 4.9 Hz, 1H), 7.59 (d, J = 8.5 Hz, 1H), 7.51 (dd, J = 8.3, 4.2 Hz, 1H), 7.49 (d, J = 9.2 Hz, 1H), 7.34 (d, J = 8.5 Hz, 1H), 7.24 (d, J = 7.2 Hz, 1H), 7.04 (t, J = 7.1 Hz, 1H), 6.99 (d, J = 9.0 Hz, 1H), 6.77 (d, J = 7.9 Hz, 1H), 6.72 (t, J = 7.4 Hz, 1H), 6.46 (d, J = 4.9 Hz, 1H), 2.23 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 167.64 (s), 161.85 (s), 157.94 (s), 155.36 (s), 150.18 (s), 148.47 (s), 138.47(s), 136.39 (s), 129.22 (s), 128.76 (s), 128.12 (s), 127.85 (s), 127.80 (s), 125.59 (s), 121.89 (s), 119.01 (s), 116.93 (s), 115.63 (s), 110.29 (s), 48.89 (s), 24.13 (s); HRMS (ESI) m/z calcd. for C21H18N4O2 [M + H]+: 359.1503, found: 359.1509.
2-Methyl-7-((4-methylpyrimidin-2-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (48): white solid, yield: 25% (64 mg), m.p.: 123–125 °C, C23H19F3N4O; 1H-NMR (500 MHz, DMSO) δ 9.59 (s, 1H), 8.19–8.15 (m, 2H), 8.09 (d, J = 9.4 Hz, 1H), 7.69–7.64 (m, 3H), 7.59 (d, J = 8.3 Hz, 2H), 7.42 (d, J = 8.4 Hz, 1H), 7.36 (d, J = 8.6 Hz, 1H), 7.07 (d, J = 9.4 Hz, 1H), 6.52 (d, J = 5.0 Hz, 1H), 2.70 (s, 3H), 2.26 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 167.96 (s), 162.04 (s), 158.23 (s), 157.51 (s), 149.14 (s), 148.73 (s), 137.80 (s), 136.56 (s), 128.09 (s), 127.52 (q, J = 31.6 Hz), 126.17 (s), 126.09 (s), 125.57 (q, J = 3.5 Hz), 124.81 (q, J = 271.9 Hz), 124.77 (s), 123.09 (s), 117.87 (s), 110.83 (s), 52.08 (s), 25.14 (s), 24.12 (s); HRMS (ESI) m/z calcd. for C23H19F3N4O [M + H]+: 425.1584, found: 425.1585.

3.2. Cell Culture

U251 MG cell line was a gift from Szabolcs Bellyei, the University of Pecs (originally obtained from American Type Culture Collection, Manassas, VA, USA). Cells were grown at 37 °C under 5% CO2 and 100% humidity in Roswell Park Memorial Institute (RPMI) medium supplemented with 10% fetal calf serum (FCS) (Sigma-Aldrich, Budapest, Hungary), and penicillin-streptomycin antibiotics.

3.3. End Point Cytoprotection Assay

For cytoprotection assays, 104 cells were seeded into each well of 96-well cell culture plates (Costar, Corning Inc., Corning, NY, USA) in culture medium containing 10% FCS. The following day, cells were treated with an increasing concentration of test compounds in the presence of 250 μM H2O2 (Sigma-Aldrich, Budapest, Hungary). The H2O2 concentration to elicit cell injury was predetermined in a pilot experiment (data not shown) and was set to induce a decrease in viability of 65–75% after 24 h Plate-to-plate variation was monitored using a dilution series of a known cytoprotective compound that was tested on each plate. Cell viability was recorded 24 h after treatment. Resazurin reagent (Sigma-Aldrich) was dissolved in phosphate buffered saline (PBS, pH 7.4) at 0.15 mg/mL concentration, sterile filtered (0.22 µm, Merck Millipore, Budapest, Hungary), aliquoted and stored at −20 °C. Samples were treated with a final concentration of 25 µg/mL resazurin. After 2 h of incubation at 37 °C 5% CO2, fluorescence (530 nm excitation/580 nm emission) was recorded on a multimode microplate reader (Cytofluor4000, PerSeptive Biosystems, Foster City, CA, USA). Viability was calculated in relation to untreated control cells and blank wells containing media without cells. The presented IC50 values (half maximal inhibitory concentration) were determined based on dose-response curves plotted in GraphPad Prism® 5.

3.4. Real-Time Cell Electronic Sensing (RT-CES) Cytoprotection Assay

A RT cytoprotection assay was performed as previously described [42,48]. Briefly, RT-CES 96-well E-plate (Roche, Hungary) was coated with gelatin solution (0.2% in PBS) for 20 min at 37 °C, then gelatin was washed twice with PBS solution. Growth media (50 μL) was then gently dispensed into each well of the 96-well E-plate for background readings by the RT-CES system prior to addition of 50 μL of the cell suspension containing 104 U251 MG cells. Plates were kept at room temperature in a tissue culture hood for 30 min prior to insertion into the RT-CES device in the incubator to allow cells to settle. Cell growth was monitored overnight by measurements of electrical impedance every 15 min. Continuous recording of impedance in cells was reflected by cell index value. Next day, cells were co-treated with 250 μM H2O2 and test compounds. Treated and control wells were dynamically monitored over 48 h by measurements of electrical impedance every 5 min. The raw plate reads for each titration point were normalized relative to the cell index status right before treatment. Each treatment was repeated in three wells per plate during the experiments.

3.5. Detection of Mitochondrial Membrane Potential

Mitochondrial membrane potential was measured as described previously [49] U251 cells (6 × 104) were plated in 24-well tissue culture plates (Corning Life Sciences, Corning, NY, USA) in RPMI 10% FCS and were treated in 500 µL media containing 500 µM H2O2 with or without test compounds. Untreated controls cells were supplemented with 500 µL cell culture media. After 2 h, the supernatants were harvested. Cells were washed with PBS, trypsinized, pooled with the corresponding supernatant, and centrifuged (2000 rpm, 5 min). The pellet was resuspended and incubated for 15 min in 5 µg/mL JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolocarbocyanine iodide, Chemodex) containing media in final volume 300 µL at 37 °C. Finally, using FL2 (585/42 nm) -FL1 (530/30 nm) channels, the red–green fluorescence intensity of 6 × 103 events was acquired immediately on a FACSCalibur flow cytometer. Data were analyzed using CellQuestTM software (CellQuest Pro v5.1, Becton Dickinson, Franklin Lakes, NJ, USA) gating out debris. Bar graphs show the percentage of FL1 positive cells visualized by GraphPad Prism® 5. For significance analysis, a Student’s t-test was applied in Microsoft Excel.

3.6. Gene Expression Analysis

The day before measurement, U-251 MG cells were seeded in 24-well microtiter plates with 100,000 cells/well density. Cells were treated with either vehicle (solvent control; ≤0.01% DMSO) or with 8-HQ analogues: 21, 34, 47, and 48 at two different concentrations: 100 nM or 300 nM. After 6 hours of incubation the medium was removed, and cells were rinsed with PBS. Cells were collected for RNA isolation in RA1 Lysis Buffer (Macherey-Nagel, Germany) supplemented with 1% beta-mercaptoethanol. Total RNA was purified with the Direct-zol kit (Zymo Research, Irvine, CA, USA) according to the manufacturer’s protocol. Total RNA was converted into complementary DNA (cDNA) using the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA) in a volume of 10 µL. 0.75 µL cDNA template was used (19 ng) in each PCR reaction. Quantitative real-time PCR was performed on the LightCycler 96 instrument (Roche) with gene-specific primers and the SYBRGreen protocol. NormFinder software [50] was used to calculate the most suitable housekeeping genes (TUBB and PPIA) for relative expression ratio calculation. For significance analysis, a Student’s t-test was applied in Microsoft Excel. Table 4 lists the primer sequences used.

4. Conclusions

Our synthesized 8HQ analogs were tested for cytoprotective activity in different assays and a handful of compounds were selected for further test. As expected, maintenance of mitochondrial membrane potential in oxidative stress was a key factor for their activity. Induction of hypoxia related genes under the regulation of HIF1A may be a crucial mechanistic step for cytoprotective activity. Based on our results, lead compounds will be further tested in animal models of different CNS diseases where oxidative stress is involved.

5. Patents

Compounds described in the current study are protected by patent #WO2011148208.

Supplementary Materials

The following are available online (1H, 13C-NMR and HRMS spectra of 1–48).

Author Contributions

Conceptualization: L.G.P., I.K., L.H.J.; Writing—Original Draft Preparation: I.K., L.H.J.; Chemical synthesis and analytical studies: I.K., R.M., M.G.; Biological evaluation: L.H.J. (screening), G.J.S. (FACS based MMP studies), O.H. (gene expression analysis).

Funding

This study was supported by a grant from the National Development Agency of Hungary (TÀMOP-4.2.2-08/1/KMR-2008-004). Gábor J. Szebeni was supported by János Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00139/17/8).

Conflicts of Interest

László G. Puskás is the owner of Avidin Ltd and Avicor Ltd. Other authors declare no conflict of interest.

References

  1. Oliveri, V.; Vecchio, G. 8-Hydroxyquinolines in medicinal chemistry: A structural perspective. Eur. J. Med. Chem. 2016, 120, 252–274. [Google Scholar] [CrossRef] [PubMed]
  2. Phillips, J.P.; Keown, R.; Fernand, Q. The reaction of anils with 8-quinolinol. J. Org. Chem. 1954, 19, 907–909. [Google Scholar] [CrossRef]
  3. Phillips, J.P.; Keown, R.; Fernand, Q. The reaction of aldehydes and aromatic amines with 8-Quinolinol. J. Am. Chem. Soc. 1953, 75, 4306–4307. [Google Scholar] [CrossRef]
  4. Sosič, I.; Mirković, B.; Arenz, K.; Štefane, B.; Kos, J.; Gobec, S. Development of new cathepsin B inhibitors: Combining bioisosteric replacements and structure-based design to explore the structure–activity relationships of nitroxoline derivatives. J. Med. Chem. 2013, 56, 521–533. [Google Scholar] [CrossRef] [PubMed]
  5. Swale, D.R.; Kurata, H.; Kharade, S.V.; Sheehan, J.H.; Raphemot, R.R.; Voigtritter, K.R.; Figueroa, E.; Meiler, J.; Flobaum, A.L.; Lindsley, C.W.; et al. ML418: The first selective, sub-micromolar pore blocker of Kir7.1 potassium channels. ACS Chem. Neurosci. 2016, 7, 1013–1023. [Google Scholar] [CrossRef] [PubMed]
  6. Mirkovic, B.; Renko, M.; Turk, S.; Sosic, I.; Jevnikar, Z.; Obermajer, N.; Turk, D.; Gobec, S.; Kos, J. Novel mechanism of cathepsin B inhibition by antibiotic nitroxoline and related compounds. ChemMedChem 2011, 6, 1351–1356. [Google Scholar] [CrossRef] [PubMed]
  7. Zeng, G.Z.; Pan, X.L.; Tan, N.H.; Xiong, J.; Zhang, Y.M. Natural biflavones as novel inhibitors of cathepsin B and K. Eur. J. Med. Chem. 2006, 41, 1247–1252. [Google Scholar] [CrossRef] [PubMed]
  8. Schenker, P.; Alfarano, P.; Kolb, P.; Caflisch, A.; Baici, A. A double-headed cathepsin B inhibitor devoid of warhead. Protein Sci. 2008, 17, 2145–2155. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Thinnes, C.C.; Tumber, A.; Yapp, C.; Scozzafava, G.; Yeh, T.; Chan, M.C.; Tran, T.A.; Hsu, K.; Tarhonskaya, H.; Walport, L.J.; et al. Betti reaction enables efficient synthesis of 8-hydroxyquinoline inhibitors of 2-oxoglutarate oxygenases. Chem. Commun. 2015, 51, 15458–15461. [Google Scholar] [CrossRef] [PubMed]
  10. Kenyon, V.; Rai, G.; Jadhav, A.; Schultz, L.; Armstrong, M.; Jameson, J.B.; Perry, S.II.; Joshi, N.; Bougie, J.M.; Leister, W.; et al. Discovery of potent and selective inhibitors of human platelet type 12-lipoxygenase. J. Med. Chem. 2011, 54, 5485–5497. [Google Scholar] [CrossRef] [PubMed]
  11. Enquist, P.-A.; Gylfe, Å.; Hägglund, U.; Lindström, P.; Norberg-Scherman, H.; Sundin, C.; Elofsson, M. Derivatives of 8-hydroxyquinoline-antibacterial agents that target intra- and extracellular Gram-negative pathogens. Bioorg. Med. Chem. Lett. 2012, 22, 3550–3553. [Google Scholar] [CrossRef] [PubMed]
  12. Chen, H.-L.; Chang, C.-Y.; Lee, H.-T.; Lin, H.-H.; Lu, P.-J.; Yang, C.-N.; Shiau, C.-W.; Shawb, A.Y. Synthesis and pharmacological exploitation of clioquinol-derived copper-binding apoptosis inducers triggering reactive oxygen species generation and MAPK pathway activation. Bioorgan. Med. Chem. 2009, 17, 7239–7247. [Google Scholar] [CrossRef] [PubMed]
  13. Shaw, A.J.; Chang, C.-Y.; Hsu, M.-Y.; Lu, P.-J.; Yang, C.-N.; Chen, H.-L.; Lo, C.-W.; Shiau, C.-W.; Chern, M.-K. Synthesis and structure-activity relationship study of 8-hydroxyquinoline-derived Mannich bases as anticancer agents. Eur. J. Med. Chem. 2010, 45, 2860–2867. [Google Scholar] [CrossRef] [PubMed]
  14. Bhat, S.; Shim, J.S.; Zhang, F.; Chong, C.R.; Jun, O.; Liu, J.O. Substituted oxines inhibit endothelial cell proliferation and angiogenesis. Org. Biomol. Chem. 2012, 10, 2979–2992. [Google Scholar] [CrossRef] [PubMed]
  15. Ibach, B.; Haen, E.; Marienhagen, J.; Hajak, G. Clioquinol treatment in familiar early onset of Alzheimer’s disease: A case report. Pharmacopsychiatry 2005, 38, 178–179. [Google Scholar] [CrossRef] [PubMed]
  16. Regland, B.; Lehmann, W.; Abedini, I.; Blennow, K.; Jonsson, M.; Karlsson, I.; Sjogren, M.; Wallin, A.; Xilinas, M.; Gottfries, C.G. Treatment of Alzheimer’s disease with clioquinol. Dement. Geriatr. Cogn. 2001, 12, 408–414. [Google Scholar] [CrossRef] [PubMed]
  17. Ritchie, C.W.; Bush, A.I.; Masters, C.L. Metal-protein attenuating compounds and Alzheimer’s disease. Expert Opin. Inv. Drug 2004, 13, 1585–1592. [Google Scholar]
  18. Raman, B.; Ban, T.; Yamaguchi, K.; Sakai, M.; Kawai, T.; Naiki, H.; Goto, Y. Metal Ion-dependent effects of clioquinol on the fibril growth of an amyloid β PEPTIDE. J. Biol. Chem. 2005, 280, 16157–16162. [Google Scholar] [CrossRef] [PubMed]
  19. Faux, N.G.; Ritchie, C.W.; Gunn, A.; Rembach, A.; Tsatsanis, A.; Bedo, J.; Harrison, J.; Lannfelt, L.; Blennow, K.; Zetterberg, H.; et al. PBT2 rapidly improves cognition in alzheimer’s disease: Additional phase II analyses. J. Alzheimers Dis. 2010, 20, 509–516. [Google Scholar] [CrossRef] [PubMed]
  20. Adlard, P.A.; Cherny, R.A.; Finkelstein, D.I.; Gautier, E.; Robb, E.; Cortes, M.; Volitakis, I.; Liu, X.; Smith, J.P.; Perez, K.; et al. Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008, 59, 48–55. [Google Scholar] [CrossRef] [PubMed]
  21. Barnham, K.J.; Gautier, E.C.L.; Kok, G.B.; Krippner, G. 8-Hydroxy Quinoline Derivatives. U.S. Patent 2015335635, 26 November 2015. [Google Scholar]
  22. Liang, S.H.; Southon, A.G.; Fraser, B.H.; Krause-Heuer, A.M.; Zhang, B.; Shoup, T.M.; Lewis, R.; Volitakis, I.; Han, Y.; Greguric, I.; et al. Novel fluorinated 8-Hydroxyquinoline based metal ionophores for exploring the metal hypothesis of Alzheimer’s disease. ACS Med. Chem. Lett. 2015, 6, 1025–1029. [Google Scholar] [CrossRef] [PubMed]
  23. Prachayasittikul, V.; Prachayasittikul, S.; Ruchirawat, S.; Prachayasittikul, V. 8-Hydroxyquinolines: A review of their metal chelating properties and medicinal applications. Drug. Des. Dev. Ther. 2013, 7, 1157–1178. [Google Scholar] [CrossRef] [PubMed]
  24. Zheng, H.; Gal, S.; Weiner, L.M.; Bar-Am, O.; Warshawsky, A.; Fridkin, M.; Youdim, M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: In vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 2005, 95, 68–78. [Google Scholar] [CrossRef] [PubMed]
  25. Zheng, H.; Youdim, M.B.H.; Fridkin, M. Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities. ACS Chem. Neurosci. 2010, 1, 737–746. [Google Scholar] [CrossRef] [PubMed]
  26. Wu, M.Y.; Esteban, G.; Brogi, S.; Shionoya, M.; Wang, L.; Campiani, G.; Unzeta, M.; Inokuchi, T.; Butini, S.; Marco-Contelles, J. Donepezil-like multifunctional agents: Design, synthesis, molecular modelling and biological evaluation. Eur. J. Med. Chem. 2015, 121, 864–879. [Google Scholar] [CrossRef] [PubMed]
  27. Wang, L.; Esteban, G.; Ojima, M.; Bautista-Aguilera, O.M.; Inokuchi, T.; Moraleda, I.; Iriepa, I.; Samadi, A.; Youdim, M.B.H.; Romero, A.; et al. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2014, 80, 543–561. [Google Scholar] [CrossRef] [PubMed]
  28. Unzeta, M.; Esteban, G.; Bolea, I.; Fogel, W.A.; Ramsay, R.R.; Youdim, M.B.H.; Tipton, K.F.; Marco-Contelles, J. Multi-target directed donepezil-like ligands for Alzheimer’s disease. Front. Neurosci. Switz. 2016, 10, 205. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Fernandez-Bachiller, M.I.; Perez, C.; Gonzalez-Munoz, G.C.; Conde, S.; Lopez, M.G.; Villarroya, M.; Garcıa, A.G.; Rodrıguez-Franco, M.I. Novel tacrine−8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer’s disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. J. Med. Chem. 2010, 53, 4927–4937. [Google Scholar] [CrossRef] [PubMed]
  30. Song, Y.; Xu, H.; Chen, W.; Zhan, P.; Liu, X. 8-Hydroxyquinoline: A privileged structure with a broad-ranging pharmacological potential. MedChemComm 2015, 6, 61–74. [Google Scholar] [CrossRef]
  31. Warshawsky, A.; Youdim, M.B.H.; Ben-Shachar, D. Pharmaceutical Compositions Comprising Iron Chelators for the Treatment of Neurodegenerative Disorders and Some Novel Iron Chelators. U.S. Patent 6855711, 15 February 2005. [Google Scholar]
  32. Youdim, M.B.H. The path from anti parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti alzheimer drugs ladostigil and M30. Curr. Alzheimer Res. 2006, 3, 541–550. [Google Scholar] [CrossRef] [PubMed]
  33. Gal, S.; Zheng, H.; Fridkin, M.; Youdim, M.B.H. Restoration of nigrostriatal dopamine neurons in post-mptp treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox. Res. 2010, 17, 15–27. [Google Scholar] [CrossRef] [PubMed]
  34. Weinreb, O.S.; Mandel, O.; Bar-Am, M.; Yogev-Falach, Y.; Avramovich-Tirosh, T.; Amit, M.B. Youdim, multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer’s disease drugs. Neurotherapeutics 2009, 6, 163–174. [Google Scholar] [CrossRef] [PubMed]
  35. Wang, Q.; Zhang, X.; Chen, S.; Zhang, S.; Youdium, M.; Le, W. prevention of motor neuron degeneration by novel iron chelators in sod1g93a transgenic mice of amyotrophic lateral sclerosis. Neurodegener. Dis. 2011, 8, 310–321. [Google Scholar] [CrossRef] [PubMed]
  36. Benkler, C.; Offen, D.; Melamed, E.; Kupershmidt, L.; Amit, T.; Mandel, S.; Youdim, M.B.H.; Weinreb, O. Recent advances in amyotrophic lateral sclerosis research: Perspectives for personalized clinical application. EPMA J. 2010, 1, 343–361. [Google Scholar] [CrossRef] [PubMed]
  37. Prati, F.; Bergamini, C.; Fato, R.; Soukup, O.; Korabecny, J.; Andrisano, V.; Bartolini, M.; Bolognesi, M.L. Novel 8-hydroxyquinoline derivatives as multitarget compounds for the treatment of alzheimer’s disease. ChemMedChem. 2016, 11, 1284–1295. [Google Scholar] [CrossRef] [PubMed]
  38. Gomes, L.M.F.; Vieira, R.P.; Jones, M.R.; Wang, M.C.P.; Dyrager, C.; Souza-Fagundes, E.M.; Da Silva, J.G.; Storr, T.; Beraldo, H. 8-hydroxyquinoline schiff-base compounds as antioxidants and modulators of copper-mediated Aβ peptide aggregation. J. Inorg. Biochem. 2014, 139, 106–116. [Google Scholar] [CrossRef] [PubMed]
  39. Cukierman, D.S.; Pinheiro, A.B.; Castiñeiras-Filho, S.L.P.; da Silva, A.S.; Miotto, M.C.; De Falco, A.; de Ribeiro, T.P.; Maisonette, S.; da Cunha, A.L.M.P.; Hauser-Davis, R.A.; et al. A moderate metal-binding hydrazone meets the criteria for a bioinorganic approach towards Parkinson’s disease: Therapeutic potential, blood-brain barrier crossing evaluation and preliminary toxicological studies. J. Inorg. Biochem. 2017, 17, 160–168. [Google Scholar]
  40. Tardiff, D.F.; Tucci, M.L.; Caldwell, K.A.; Caldwell, G.A.; Lindquist, S. Different 8-hydroxyquinolines protect models of TDP-43 protein, α-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J. Biol. Chem. 2012, 287, 4107–4120. [Google Scholar] [CrossRef] [PubMed]
  41. Youdim, M.B.H.; Fridkin, M.; Zheng, H. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson’s disease and other neurodegenerative diseases. J. Neural Transm. 2004, 111, 1455–1471. [Google Scholar] [CrossRef] [PubMed]
  42. Ózsvári, B.; Puskás, L.G.; Nagy, L.I.; Kanizsai, I.; Gyuris, M.; Madácsi, R.; Fehér, L.Z.; Gerő, D.; Szabó, C. A cell-microelectronic sensing technique for the screening of cytoprotective compounds. Int. J. Mol. Med. 2010, 25, 525–530. [Google Scholar] [PubMed]
  43. Korkmaz, S.; Barnucz, E.; Loganathan, S.; Li, S.; Radovits, T.; Hegedűs, P.; Zubarevich, A.; Hirschberg, K.; Weymann, A.; Puskás, L.G.; et al. Q50, an Iron-Chelating and zinc-complexing agent, improves cardiac function in rat models of ischemia/reperfusion-induced myocardial injury. Circ. J. 2013, 77, 1817–1826. [Google Scholar] [CrossRef] [PubMed]
  44. Darvas, F.; Dorman, G.; Krajcsi, P.; Puskas, L.G.; Kovari, Z.; Lorincz, Z.; Urge, L. Recent advances in chemical genomics. Curr. Med. Chem. 2004, 11, 3119–3145. [Google Scholar] [CrossRef] [PubMed]
  45. Vayssier-Taussat, M.; Kreps, S.E.; Adrie, C.; Dall’Ava, J.; Christiani, D.; Polla, B.S. Mitochondrial membrane potential: A novel biomarker of oxidative environmental stress. Environ. Health Persp. 2002, 110, 301–305. [Google Scholar] [CrossRef]
  46. Ogunshola, O.O.; Antoniou, X. Contribution of hypoxia to Alzheimer’s disease: Is HIF-1alpha a mediator of neurodegeneration? Cell. Mol. Life Sci. 2009, 22, 3555–3563. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Ryou, M.G.; Liu, R.; Ren, M.; Sun, J.; Mallet, R.T.; Yang, S.H. Pyruvate protects the brain against ischemia-reperfusion injury by activating the erythropoietin signaling pathway. Stroke 2012, 43, 1101–1107. [Google Scholar] [CrossRef] [PubMed]
  48. Antal, O.; Hackler, L.J.; Shen, J.; Mán, I.; Hideghéty, K.; Kitajka, K.; Puskás, L.G. Combination of unsaturated fatty acids and ionizing radiation on human glioma cells: Cellular, biochemical and gene expression analysis. Lipids Health Dis. 2014, 13, 142. [Google Scholar] [CrossRef] [PubMed]
  49. Szebeni, G.J.; Balázs, Á.; Madarász, I.; Pócz, G.; Ayaydin, F.; Kanizsai, I.; Fajka-Boja, R.; Alföldi, R.; Hackler, L., Jr.; Puskás, L.G. Achiral mannich-base curcumin analogs induce unfolded protein response and mitochondrial membrane depolarization in PANC-1 cells. Int. J. Mol. Sci. 2017, 18, 2105. [Google Scholar] [CrossRef] [PubMed]
  50. Andersen, C.L.; Jensen, J.L.; Ørntoft, T.F. Normalization of real-time quantitative RT-PCR data: A model based variance estimation approach to identify genes suited for normalization applied to bladder- and colon-cancer data-sets. Cancer Res. 2004, 64, 5245–5250. [Google Scholar] [CrossRef] [PubMed]
Sample Availability: Samples of the compounds are not available from the authors.
Molecules 23 01934 g001 550
Figure 1. Cytotoxic 8-hydroxyquinoline (8-HQ) analogues.
Figure 1. Cytotoxic 8-hydroxyquinoline (8-HQ) analogues.
Molecules 23 01934 g001
Molecules 23 01934 g002 550
Figure 2. Cytoprotective 8-HQ derivatives.
Figure 2. Cytoprotective 8-HQ derivatives.
Molecules 23 01934 g002
Molecules 23 01934 sch001 550
Scheme 1. General protocol for the synthesis of compounds 1–48.
Scheme 1. General protocol for the synthesis of compounds 1–48.
Molecules 23 01934 sch001
Molecules 23 01934 sch002 550
Scheme 2. The tested basic chemical library with half maximal inhibitory concentration (IC50) values in a cytoprotection assay. Each analog was prepared with the combination of the shown aldehydes, substituted amines, and 8-HQ.
Scheme 2. The tested basic chemical library with half maximal inhibitory concentration (IC50) values in a cytoprotection assay. Each analog was prepared with the combination of the shown aldehydes, substituted amines, and 8-HQ.
Molecules 23 01934 sch002
Molecules 23 01934 g003a 550Molecules 23 01934 g003b 550
Figure 3. Real-time cytoprotection assay. (A): Real-time viability data traces of the most active 34 analog were followed for 60 h after treatment. (B): Cytoprotective activity of the tested compounds 24 h after treatment. Percentages were calculated in relation to non-treated and hydrogen peroxide-only treated cell data. (C): Comparison of IC50 values determined from the primary (resazurin, end-point) assay and the real time assay 24 h after treatment.
Figure 3. Real-time cytoprotection assay. (A): Real-time viability data traces of the most active 34 analog were followed for 60 h after treatment. (B): Cytoprotective activity of the tested compounds 24 h after treatment. Percentages were calculated in relation to non-treated and hydrogen peroxide-only treated cell data. (C): Comparison of IC50 values determined from the primary (resazurin, end-point) assay and the real time assay 24 h after treatment.
Molecules 23 01934 g003aMolecules 23 01934 g003b
Molecules 23 01934 g004 550
Figure 4. Mitochondrial membrane depolarization assay. Treatment with the synthesized analogs reversed the mitochondrial membrane potential changes caused by oxidative stress. All data was calculated by relation to hydrogen peroxide only treatment set to 1. Statistical significance (t-test): * p < 0.05 and ** p < 0.01.
Figure 4. Mitochondrial membrane depolarization assay. Treatment with the synthesized analogs reversed the mitochondrial membrane potential changes caused by oxidative stress. All data was calculated by relation to hydrogen peroxide only treatment set to 1. Statistical significance (t-test): * p < 0.05 and ** p < 0.01.
Molecules 23 01934 g004
Molecules 23 01934 g005 550
Figure 5. Induction of hypoxia-related gene and glucose transporter expression. HIF1A-regulated genes were activated following treatment with selected analogs in a dose- and cytoprotective activity-dependent manner. Statistical significance (t-test): * p < 0.05 and ** p < 0.01.
Figure 5. Induction of hypoxia-related gene and glucose transporter expression. HIF1A-regulated genes were activated following treatment with selected analogs in a dose- and cytoprotective activity-dependent manner. Statistical significance (t-test): * p < 0.05 and ** p < 0.01.
Molecules 23 01934 g005
Table
Table 1. Betti-three components reactions (3CR) results, use of several anilines and aldehydes (Subclass 1).
Table 1. Betti-three components reactions (3CR) results, use of several anilines and aldehydes (Subclass 1).
Molecules 23 01934 i001
CompoundsAmine (R′)Aldehyde (R″)Yield (%) aIC50 (µM)SD
16 Molecules 23 01934 i002 Molecules 23 01934 i006300.1950.143
17 Molecules 23 01934 i003 Molecules 23 01934 i007600.1220.029
18 Molecules 23 01934 i004 Molecules 23 01934 i008330.0960.033
19 Molecules 23 01934 i005 Molecules 23 01934 i009140.1250.024
a after column chromatography and crystallization.
Table
Table 2. Functionalization with several picolines (Subclass 2).
Table 2. Functionalization with several picolines (Subclass 2).
Molecules 23 01934 i010
CompoundsAmine (R′)Aldehyde (R″)RYield (%) aIC50 (µM)SD
20 Molecules 23 01934 i011 Molecules 23 01934 i024H330.0870.028
21 Molecules 23 01934 i012 Molecules 23 01934 i025H510.0860.046
22 Molecules 23 01934 i013 Molecules 23 01934 i026Me230.5620.136
23 Molecules 23 01934 i014 Molecules 23 01934 i027Me710.8240.390
24 Molecules 23 01934 i015 Molecules 23 01934 i028H340.1350.073
25 Molecules 23 01934 i016 Molecules 23 01934 i029H620.1560.052
26 Molecules 23 01934 i017 Molecules 23 01934 i030H180.1660.040
27 Molecules 23 01934 i018 Molecules 23 01934 i031H150.1560.078
28 Molecules 23 01934 i019 Molecules 23 01934 i032H350.2060.168
29 Molecules 23 01934 i020 Molecules 23 01934 i033H430.3790.217
30 Molecules 23 01934 i021 Molecules 23 01934 i034H900.2460.171
31 Molecules 23 01934 i022 Molecules 23 01934 i035H220.4600.199
32 Molecules 23 01934 i023 Molecules 23 01934 i036H530.2040.111
a after column chromatography and crystallization.
Table
Table 3. Functionalization with several pyrimidines (Subclass 3).
Table 3. Functionalization with several pyrimidines (Subclass 3).
Molecules 23 01934 i037
CompoundsAmine (R′)Aldehyde (R″)RYield (%) aIC50 (µM)SD
33 Molecules 23 01934 i038 Molecules 23 01934 i054H320.1380.077
34 Molecules 23 01934 i039 Molecules 23 01934 i055H460.1190.080
35 Molecules 23 01934 i040 Molecules 23 01934 i056H190.1140.095
36 Molecules 23 01934 i041 Molecules 23 01934 i057H680.1400.152
37 Molecules 23 01934 i042 Molecules 23 01934 i058H160.1630.109
38 Molecules 23 01934 i043 Molecules 23 01934 i059H180.1490.067
39 Molecules 23 01934 i044 Molecules 23 01934 i060H290.1350.098
40 Molecules 23 01934 i045 Molecules 23 01934 i061H400.0730.021
41 Molecules 23 01934 i046 Molecules 23 01934 i062H310.1690.129
42 Molecules 23 01934 i047 Molecules 23 01934 i063H590.4130.240
43 Molecules 23 01934 i048 Molecules 23 01934 i064H160.1190.050
44 Molecules 23 01934 i049 Molecules 23 01934 i065H250.1390.064
45 Molecules 23 01934 i050 Molecules 23 01934 i066H150.3130.067
46 Molecules 23 01934 i051 Molecules 23 01934 i067H150.1830.157
47 Molecules 23 01934 i052 Molecules 23 01934 i068H150.4810.082
48 Molecules 23 01934 i053 Molecules 23 01934 i069Me250.8870.226
a after column chromatography and crystallization.
Table
Table 4. Primer sequences for Quantitative real-time PCR (qRT-PCR) analysis.
Table 4. Primer sequences for Quantitative real-time PCR (qRT-PCR) analysis.
Gene NameAbbreviationForward_SequenceReverse_Sequence
Tubulin beta class ITUBBataccttgaggcgagcaaaactgatcacctcccagaacttg
Peptidylprolyl isomerase APPIAatgctggacccaacacaaattctttcactttgccaaacacc
Heme oxygenase 1HMOX1ggcagagggtgatagaagaggagctcctgcaactcctcaaa
Vascular endothelial growth factorVEGFgcagcttgagttaaacgaacgggttcccgaaaccctgag
Solute carrier family 2 member 1GLUT1ccccatcccatggttcatctgaggtccagttggagaagc

Share and Cite

MDPI and ACS Style

Kanizsai, I.; Madácsi, R.; Hackler Jr., L.; Gyuris, M.; Szebeni, G.J.; Huzián, O.; Puskás, L.G. Synthesis and Cytoprotective Characterization of 8-Hydroxyquinoline Betti Products. Molecules 2018, 23, 1934. https://doi.org/10.3390/molecules23081934

AMA Style

Kanizsai I, Madácsi R, Hackler Jr. L, Gyuris M, Szebeni GJ, Huzián O, Puskás LG. Synthesis and Cytoprotective Characterization of 8-Hydroxyquinoline Betti Products. Molecules. 2018; 23(8):1934. https://doi.org/10.3390/molecules23081934

Chicago/Turabian Style

Kanizsai, Iván, Ramóna Madácsi, László Hackler Jr., Márió Gyuris, Gábor J. Szebeni, Orsolya Huzián, and László G. Puskás. 2018. "Synthesis and Cytoprotective Characterization of 8-Hydroxyquinoline Betti Products" Molecules 23, no. 8: 1934. https://doi.org/10.3390/molecules23081934

Article Metrics

Back to TopTop